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1. INTRODUCTION 
Vitiligo is a common acquired depigmentary disease characterized by white 
patches of the skin, hair and mucous membranes due to selective destruction of 
melanocytes (Lerner and Nordlund 1978). The prevalence of vitiligo is 0.5% to 
1% in Europe and the United States, but ranges from 0.1% in China up to 8.8% 
in some regions of India (Taieb and Picardo 2007; Alikhan et al. 2011; Lu et al. 
2007; Behl and Bathia 1972). Vitiligo affects both genders equally and in 50% 
of the cases the disease appears before the age of 20 (Nordlund and Majumder 
1997). Up to now clinical types of vitiligo have not been uniformly understood 
and reliably classified. The simplest classification divides vitiligo into seg-
mental and nonsegmental types, based on the clinical course and different distri-
bution of the pattern (Koga 1977). The classification of vitiligo created by Hann 
and Nordlund is more complicated and divides vitiligo into localized and gene-
ralized types with several subtypes (Hann and Nordlund 2000d). In 2011 the 
classification of vitiligo was revised in Vitiligo Global Issue Consensus Confe-
rence (VGICC). By the consensus segmental vitiligo should be classified sepa-
rately from all the other types of vitiligo; the term “vitiligo” can be used as an 
umbrella term for all non-segmental types of vitiligo, including “mixed vitiligo” 
with combined segmental and non-segmental types, which is considered as a 
subgroup of vitiligo (Ezzedine et al. 2012). The disease has a longlasting chro-
nic course and its phenotype can change during the years (Liu et al. 2005; 
Zaima and Goga 2002). Most cases are sporadic, the incidences of familial 
vitiligo range from 10% in China up to 74% in India (Wang et al. 2013; Misri et 
al. 2009). Epidemiological studies have revealed that vitiligo is inherited in a 
non-Mendelian, multifactorial and polygenic pattern with incomplete pene-
trance (Alkhateeb et al. 2003; Sun et al. 2006). Vitiligo can associate with seve-
ral other autoimmune diseases, including thyroid disease, diabetes, pernicious 
anemia, lupus, Addison’s disease, rheumatoid arthritis, alopecia areata, pso-
riasis, asthma, chronic urticaria, inflammatory bowel disease (Dawber 1970; 
Cunliffe et al. 1968; Gould 1985; Alkhateeb et al. 2003; Zhang et al. 2009). 
The same diseases occur more frequently in patients’ first-degree relatives 
(Alkhateeb et al. 2003; Laberge et al. 2005). Vitiligo can be present in all types 
of autoimmune polyendocrine syndromes (APS), but most frequently it is as-
sociated with thyroid autoimmune disease in APS type three (Betterle 2004, 
Amerio et al. 2006). Several autoantibodies (thyroid, gastric parietal cells, anti-
adrenal cortex, antinuclear) have been detected in the sera of the patients with 
vitiligo without clinical manifestation of another autoimmune disease during the 
years (Kahaly 2009; Daneshpazhooh et al. 2006; Farrokhi 2005; Alkhateeb et 
al. 2003; Hann et al. 1993). 
Vitiligo does not cause notable physical impairment but affects human sense 
of well-being and self-esteem in a different way: it predisposes social isolation, 
depression, difficulties in sexual relationship (Mechri et al. 2006; Firooz et al. 
2004, Wang et al. 2011; Porter et al. 1990). Dermatology life quality index 
(DLQI) of vitiligo varies from 4.4 in Indonesia to 17.1 in Saudi Arabia (Chan et 
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al. 2012; Al-Mubarak et al. 2011). Females and people with dark skin colour 
are more stigmatised (Linthorst et al. 2009; Ongenae et al. 2005b; Dolatshahi et 
al. 2008). Quality of life (QoL) issues that arise from the loss of the pigment are 
the following: choice of clothes, use of sunblocks, use of camouflage, avoi-
dance of activities and negative reactions by other people (Ongenae et al. 
2005a, b; Tanioka et al. 2010). Some studies have pointed out psychiatric 
comorbidity in vitiligo, the prevalence in Europe and in India stays between 25–
35% (Picardi et al. 2001; Mattoo et al. 2002).  
The exact pathogenesis of vitiligo is still unknown. Several pathophysio-
logical theories have been proposed to explain the dysfunction or loss of 
melanocytes in the epidermis of vitiligo patients (Alikhan et al. 2011). These 
include an autoimmune mechanism, biochemical mechanism (auto-cytotoxicity 
and oxidative stress), neurohumoral mechanism and a decreased melanocyte 
survival hypothesis (Ongena et al. 2003; Schallrauter et al. 1999a; Moretti et al. 
2002; Lee et al. 2005a). The convergence theory comprises all these mecha-
nisms and states that autoimmunity, mutations, stress, accumulation of toxic 
compounds, altered cellular environments and impaired melanocyte migration 
all contribute to pathogenesis of vitiligo and it depends on the patient which 
mechanism dominates (Le Poole et al. 1993). 
Dysfunction of the neural regulation has been shown in different auto-
immune and inflammatory disorders. Dysregulation of the nervous system at a 
central or local level may damage melanocytes also in vitiligo. The importance 
of central neuroendocrine system emerges at the onset or aggravation of pig-
ment loss during or after increased stress period in vitiligo up to 62.5% of the 
cases (Firooz et al. 2004). The melanocortin system is a part of the neuro-
endocrine system. It consists of five melanocortin receptors (MCR1-MCR5), 
four agonists of these receptors (α-, β-, γ- melanocyte-stimulating hormone and 
adrenocorticotropic hormone) and two antagonists of melanocortin receptors: 
agouti and agouti-related protein (Gantz and Fong 2003). The expressional level 
of the peptides of the melanocortin system is highest in the brain, but it involves 
also peripheral tissues, including the skin, where these peptides are secreted by 
the keratinocytes and melanocytes (Kono et al. 2001). The melanocortin system 
completes different functions in the skin associated with response to the stress, 
it regulates pigmentation, inflammation, exocrine secretion, analgesia, immuno-
modulation and temperature control (Gantz and Fong 2003; Slominski et al. 
2000; Eves and Haycock 2010).  
Vitiligo as a disease has received little scientific attention in the Nordic 
countries. There are no previous studies analyzing the mRNA ecxpression 
levels of the melanocortin system in vitiligo. 
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2. REVIEW OF THE LITERATURE 
2.1. Epidemiology, clinical types,  
triggering factors and course of vitiligo 
2.1.1. Epidemiology of vitiligo 
Vitiligo is a common acquired depigmentary disease characterized by white 
patches of the skin, hair and mucous membranes due to selective destruction of 
melanocytes (Lerner and Nordlund 1978). The disease occurs with an estimated 
prevalence of 0.15–3.0% in Western Europe and in Turkey, around 1% in the 
United States, 2.6–4% in Mexico, 0.1–8.8% in India and 0.1–0.6% in China 
(Dawber 1968; Perrot 1973; Arican 2003; Taieb and Picardo 2007; Alikhan et 
al. 2011; Ruiz Maldonnado 1977; Canizares 1960; Handa and Kaur 1999; 
Koranne and Sachdeva 1988; Behl and Bathia 1972; Lu et al. 2007; Xu et al. 
2002; Wang et al. 2013). The latest review based on published epidemiological 
studies has shown an estimated worldwide prevalence of vitiligo from 0.06% to 
2.28% (Krüger and Schallreuter 2012). Gradually increasing age-specific pre-
valence has been demonstrated in vitiligo in China and Denmark: 0.1% in the 
age-group of 0 to 9 years, 0.9% in the age group of 60 to 69 years, 1.7% in the 
age-group of 70 years and over (Howitz et al. 1977; Wang et al. 2013). Most 
studies have demonstrated that vitiligo affects both sexes equally, except 
hospital-based studies where women have dominated (Alkhateeb et al. 2003; 
Boisseau-Garsaud et al. 2001). Such female superiority can be explained by the 
desire to look good and willingness to seek medical help in order to satisfy this 
desire. The loss of pigmentation can start at any age during lifetime and the 
onset age varies significantly between the studies in different regions of the 
world. The usual age of the onset of vitiligo is between 10 and 30 years and in 
half of the cases the disease starts before the age of 20 years, in 70–80% of the 
cases before the age of 30 years (Zhang et al. 2004; Liu et al. 2005; Nordlund 
and Lerner 1982). In Denmark the onset of vitiligo was observed most fre-
quently between the ages of 40 and 60 years (Howitz et al. 1977). Positive 
family history influences the onset of vitiligo and in those cases the disease 
appears earlier than in sporadic cases (Ando et al. 1993; Laberge et al. 2005). A 
hospital-based study in Greece revealed the peak prevalence in females in the 
first decade of life and in males in the fifth decade. Vitiligo was significantly 
more prevalent in young women at the age up to 30 years and in middle-aged 
men at the age 31–60 years (Kyriakis et al. 2009).  
 
 
2.1.2. Clinical types of vitiligo 
There is no uniform understanding of vitiligo clinical types and exact patho-
physiology of the disease remains unknown. Different approaches have been 
tried in classification of vitiligo but no etiopathogenetic classification as a gold 
standard has been worked out yet (Hercogova et al. 2012). The simplest 
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classification divides vitiligo into nonsegmental and segmental types based on 
different distribution pattern and clinical course of the disease (Koga 1977). A 
more complex clinical classification of vitiligo was created by Hann and Nord-
lund at the beginning of this century. According to the extension and pattern of 
pigment loss distribution, they differentiated the disease as localized, genera-
lized and universal with several subtypes (Hann and Nordlund 2000d, Table 1).  
 
 
Table 1. Clinical types and subtypes of vitiligo by Hann and Nordlund (2000). 
Type of vitiligo Subtype Description  
Localized vitiligo Focal One or more macules in one area, but not in a 
segmental distribution  
Segmental One or more macules in one area in a segmental 
distribution 
Mucosal Macules only in mucous membranes 
Generalized 
vitiligo 
Acrofacial Macules on distal extremities and the face 
Vulgaris Scattered macules with symmetrical distribution 
all over the body 
Mixed Segmental and vulgaris, segmental and acrofacial, 
acrofacial and vulgaris 
Universal vitiligo  Complete or nearly complete depigmentation 
 
 
Localized clinical subtypes of vitiligo stay at minority in most clinical studies. 
Focal vitiligo is characterized by one or a few depigmented macules in a small 
area (10–15cm2) without an obvious distribution pattern; it can be a subset of 
segmental or generalized vitiligo before the extension (Taieb and Picardo 2007). 
Focal vitiligo has been the first presentation of vitiligo from 27% to 70% of the 
cases in China and Nigeria (Zhang et al. 2009; Liu et al. 2005; Onunu and 
Kubeyinje 2003). VGICC suggests to call focal vitiligo as undertermined or un-
classified type of vitiligo until more definitive classification can be made on 
clinical grounds, generally after 1–2 years of follow-up (Ezzedine et al. 2012). 
Mucosal subtype describes isolated depigmentation of the lips, oral or genital 
mucosa. It is quite rare and more characteristic, up to 10% of the cases, for 
individuals with dark skin phototype in India (Dave et al. 2002). Cases of 
vitiligo with long-lasting focal lesions or of pure mucosal depigmentation may 
remain simply “unclassifiable” vitiligo (Ezzedine et al. 2012). Segmental viti-
ligo is defined as an “acquired chronic pigmentation disorder characterized by 
white patches in unilateral distribution that may totally or partially match a 
dermatome, but not necessarily” (Taieb and Picardo 2007). The occurrence of 
this subtype of vitiligo varies also between the studies from 2.5% to 27.9% and 
is more characteristic of childhood vitiligo (Wang et al. 2013; Koga and Tango 
1988; Halder et al. 1987; Jaisankar et al. 1992). Several patterns of segmental 
vitiligo in the facial region have been described in Korea (Hann et al. 2000a; 
Kim et al. 2011). Different clinical phenotypes of segmental vitiligo like unila-
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teral segmental, bilateral segmental, Blaschkoid, mixed segmental with gene-
ralized subtypes were described lately in Belgium and India (van Geel et al. 
2011a; Khaitan et al. 2012).  
Generalized vitiligo is the most common type of vitiligo in adults and vitili-
go vulgaris has been the most frequent clinical pattern in many published pa-
pers, comprising 39–83% of the subjects (Handa and Kaur 1999; Dogra et al. 
2005; Liu et al. 2005; Mason and Gawkrodger 2005). By the definition of 
Vitiligo European Task Force vitiligo vulgaris is an acquired chronic pigmen-
tation disorder characterized by white patches, often symmetrical distribution, 
which usually increase in size with time, corresponding to a substantial loss of 
functioning epidermal and sometimes hair follicle melanocytes (Taieb and Pi-
cardo 2007). The sites of predilection for this type are hands, wrists, knees, 
elbows, axilla, groin, neck, head and body orifices (Gawkrodger et al. 2008; 
Kovacs 1998). Acrofacial vitiligo involves distal parts of the limbs and circum-
ferential pattern of the face orifices. This clinical subtype of vitiligo comprises 
3–12% in clinical studies (Handa and Kaur 1999; Wang et al. 2013; Zhang et 
al. 2009). Acrofacial vitiligo has been reported between 17% and 35% of the 
subjects in India but a similar pattern called lip-tip vitiligo (vitiligo on the lips 
and distal parts of the fingers) was described additionally in 7% of the cases as 
well (Dave et al. 2002; Martis et al. 2002). The mixed type of vitiligo is a new 
and quite confusing entity, as it comprises different clinical types of vitiligo at 
the same time on the patients body; the number of such cases reported in the 
literature is too small to understand the real nature of this type (Mulekar et al. 
2006; van Geel et al. 2011a). In universal type nearly complete (BSA > 80%) or 
complete depigmentation of the skin appears. This type presents from 0.5% to 
18% of the cases in vitiligo (Dogra et al. 2005; Wang et al. 2013). VGICC 
classification recommends to use the term “vitiligo” further as an umbrella term 
for all non-segmental forms of vitiligo including “mixed vitiligo“, in which seg-
mental and non-segmental vitiligo are combined and it is considered now as a 
subtype of vitiligo (Ezzedine et al. 2012, Table 2). 
 
Table 2. Vitiligo Global Issues Consensus Conference classification (2012). 
Type of vitiligo Subtypes 
Nonsegmental vitiligo Acrofacial 





Segmental vitiligo Uni-, bi- or plurisegmental 
Undetermined/unclassified vitiligo Focal 
Mucosal (only one site) 
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Some studies have found correlation between the disease onset and different 
clinical types in vitiligo. Segmental vitiligo has been more characteristic of 
children and young people (median age at onset 12–16 years) and was reported 
only 0–4.5% in adults (Khaitan et al. 2012; Liu et al. 2005; Berti et al. 2011; 
Dogra et al. 2005; Mason and Gawkrodger 2005).  
By classical morphology of vitiligo the lesions are discrete, uniformly 
milky-white macules with round, oval or irregular shape in size from milli-
meters to many centimeters, surrounded by normal or hyperpigmented skin 
(Ortonne 2008). The disease is asymptomatic, but in some cases itching or 
burning sensation can present (Behl and Bhatia 1972). Vitiligo prefers the sites 
of friction that are normally hyperpigmented like face, dorsal surface of the 
hands, axilla, nipples, sacrum, ingvinal and anogenital regions and the surface 
of joints. Leukotrichia develops in 3.7–47.3% of the cases of vitiligo (Handa 
and Kaur 1999; Dogra et al. 2005; Akrem et al. 2008). Mucosal involvement 
has been reported between 7.4–74% in generalized types of vitiligo (Onunu et 
al. 2003; Hann et al. 1997). 
There are some rare morphological variations of vitiligo: vitiligo ponctue’, 
tri-, quadri- and pentachrome vitiligo, blue vitiligo and inflammatory vitiligo 
(Ortonne 2008; Halder and Taliaferro 2008). Vitiligo ponctue’ shows discrete 
and confetti-like depigmented macules on normal or hyperpigmented skin 
(Ortonne 2008). Trichrome vitiligo is recognized by the presence of a narrow to 
broad intermediate colour zone between a vitiligo macule and normal pig-
mented surrounding (Hann et al. 2000b). Quadrichrome vitiligo shows four 
colours and macular perifollicular or marginal hyperpigmentation in the lesion 
and it usually occurs in darker skin phenotypes (Behl et al. 2003). Pentachrome 
vitiligo has been described in black-skinned people with variation of five 
colours: white, tan, brown, blue-gray hyperpigmentation and the normal skin 
(Fargnoli and Bolognja 1995; Zhang and Zhu 2013). Blue vitiligo has a 
blue-gray hue as a mark of postinflammatory hypermelanosis (Ivker et al. 
1994). Inflammatory vitiligo could be caused by an agressive therapy and it has 
an erythematous, raised border in a vitiligo macule with frequent itching or 
burning (Ortonne et al. 1979).  
 
 
2.1.3. Triggering factors and course of vitiligo  
In clinical studies 10–76% of the patients with generalized vitiligo can name the 
factors that have preceded the onset or exacerbation of the disease: skin injury, 
emotional stress, sunburn, hormonal changes (Behl and Bhatia 1972; Koo et al. 
1996; Verma 2009; Manolache and Benea 2007). These factors were not as-
sociated with segmental type of vitiligo (Hann and Lee 1996; Khaitan et al. 
2012). Psychological stress is the most frequently reported triggering factor in 
vitiligo, experienced by 47–65% of the patients before the onset of pigment loss 
(Boisseau-Garsaud et al. 2001; Firooz et al. 2004; Agarwal 1998; Manolache and 
Benea 2007). Very often pigment loss starts after skin trauma and prefers then the 
sites of friction, scratches or scars; such a development is known as the Koebner 
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phenomenon, originally described in psoriasis. The Koebner phenomenon has 
been observed in 5–62% of the cases in vitiligo and it is associated with the active 
stage of the disease and extensive pigment loss (Hann et al. 1997; Barona et al. 
1995; van Geel et al. 2012a). Sunburn has been recorded in up to 29% of those 
cases when the external factor was named, but suspected chemicals are seldom 
confirmed to be the triggers in vitiligo (Vrijman et al. 2013).  
The course of vitiligo is unpredictable and depends on the clinical type of the 
disease. Generally vitiligo begins insidiously in sun-exposed areas and has a 
slowly progressive lifelong course with partial spontaneous repigmentation in 
some of the lesions (Alikhan et al. 2011). Several studies have demonstrated a 
slow course in vitiligo with pigment loss under 20% of body surface area (BSA) 
up to 90% of the cases with median disease duration 4–6 years (Daneshpazhooh 
et al. 2006; Handa and Kaur 1999). BSA under 5% was shown in 78% of the 
cases of vitiligo in China with a median disease duration 18 months (Zhang et 
al. 2009). Segmental vitiligo has revealed a rapid onset in Japan with median 
progression during 0.7 years over the affected dermatomal area, after that its 
activity will cease and the disease stays stable for the rest of the patient’s life 
(Koga and Tango 1988). In clinical studies progression is defined as an active 
stage of the disease characterized by the increase of the size or number of 
depigmented macules during three months prior to examination. Progression 
has been reported between 70% and 90% of the cases in generalized vitiligo 
(Dave et al. 2002; Chun and Hann 1997). The clinical phenotype of vitiligo can 
change during the progression of the disease (Liu et al. 2005; Zaima and Koga 
2002). Some clinical characteristics like family history of vitiligo, nonsegmental 
type, long duration of the disease, the Koebner phenomenon and mucosal 
involvement have been associated with progression of vitiligo in Korea and 
India (Hann et al. 1997; Dave et al. 2002). These authors found also correlation 
between the initial site on posterior trunk, hands or feet and the disease 
progression in vitiligo (Hann et al. 1997). Vitiligo on the hands has been 
associated with disease progression to the face (Chun and Hann 1997). The 
presence of halo nevi and leukotrichia have been the factors associated with 
progression of segmental type to mixed type in vitiligo (Ezzedine et al. 2012). 
Spontaneous repigmentation has been also described in vitiligo, usually it is 






2.2. Associated diseases, the presence  
of autoimmune polyendocrine syndrome (APS) and 
autoantibodies in vitiligo 
2.2.1. Associated diseases in vitiligo 
Based on autoimmune hypothesis in pathogenesis of vitiligo, there are nume-
rous studies focused on associated diseases in vitiligo patients and also in their 
families. At present there is a long list of different concomitant disorders and 
syndromes described in vitiligo, some of them are more common and some are 
less reported (Alikhan et al. 2011, Table 3).  
 
 




Addison’s disease, alopecia areata, atopic dermatitis, 
autoimmune thyroid disease, chronic urticaria, diabetes 
mellitus, halo nevi, hypoacusis, ichthyosis, ocular 
abnormalities, pernicious anaemia, psoriasis, rheumatoid 
arthritis 
Less commonly 
associated disorders  
Acrokeratosis paraneoplastica Bazex, Alezzandrini 
syndrome, APS1, asthma, ataxia-teleangiectasia, deafness, 
dysgammaglobulinaemia, inflammatory bowel disease, 
Kabuki syndrome, Kaposi sarcoma, melanoma, MELAS 
syndrome, morphea, multiple sclerosis, myasthenia gravis, 
nonmelanoma skin cancer, pemphigus vulgaris, sarcoidosis, 
Schmidt syndrome, systemic lupus erythematosus, Turner 




Concomitant autoimmune diseases have been reported in 2% of the cases in 
Nigeria and India, 20% in USA and Japan, 55% in Turkey in vitiligo (Onunu 
and Kubeyinje 2003; Poojary 2011; Alhateeb et al. 2003; Narita et al. 2011; 
Akay et al. 2010). Patients with familial vitiligo have demonstrated high pre-
valence of autoimmune diseases in China (12%) and in the USA (37%) (Zhang 
et al. 2009; Laberge et al. 2005). In vitiligo autoimmune association has been 
more frequent in females, in generalized type of vitiligo and in acrofacial 
location (Amerio et al. 2010; Barona et al. 1995; Klisnick et al. 1998). The 
increase of incidences of autoimmune thyroiditis, pernicious anemia, Addison’s 
disease, systemic lupus erythematosus and inflammatory bowel disease in viti-
ligo have been described in the Caucasian population. The increase was not 
found in the frequencies of alopecia areata, multiple sclerosis, myasthenia 
gravis, psoriasis, rheumatoid arthritis, scleroderma and Sjogren’s syndrome 
(Alkhateeb et al. 2003). In Japan autoimmune thyroid disease (12%) and alo-
pecia areata (5.3%) have been the most often described autoimmune diseases 
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of the patients with generalized vitiligo (Narita et al. 2011). In China the pre-
valence of associated disorders in vitiligo has been investigated and compared 
with the prevalence of these disorders in general population in two large-scale 
studies with subject numbers 3742 and 6516 (Liu et al. 2005; Zhang et al. 
2009). Both studies showed lower to equal prevalence of hyper- and hypo-
thyroidism (0.8–1.3% vs 1.2% and 0.6–1.1% vs 1.0%, respectively) and higher 
prevalence of rheumatoid arthritis (2.2% vs 0.3%), chronic urticaria (0.9% vs 
0.1%), alopecia areata (0.3–0.9% vs 0.09%) in vitiligo compared with the 
prevalence in general population. The prevalence of psoriasis (0.3% vs 0.1%) 
and ichtyosis (0.3% vs 0.1%) was also increased in vitiligo compared with the 
prevalence in general population in China (Zhang et al. 2009). In Germany the 
higher prevalence of autoimmune thyroid disease (7.8%) and the higher pre-
sence of thyroid antibodies was demonstrated in vitiligo, but random prevalence 
of diabetes mellitus, alopecia areata, psoriasis, pernicious anaemia and atopic 
eczema was shown compared with the control population. No eye or inner-ear 
involvement in vitiligo was found (Schallreuter et al. 1994). In spite of that, 
some studies have demonstrated hypoacusis in up to 20% of the cases and 
ocular abnormalities like uveitis, iris and retinal hypopigmentation in up to 40% 
of the cases of vitiligo (Hong et al. 2009; Gopal et al. 2007; Cowan et al. 1986). 
These changes are usually mild and do not cause noticeable visual or hearing 
impairment for the patients. The primary reports from India and Nigeria 
revealed low incidence of thyroid disease (0.5–0.6%), but the cases could be 
underdiagnosed as they screened only subjects with clinical features (Handa and 
Kaur 1999; Onunu and Kubeyinje 2003). Later a higher prevalence of hypo-
thyroidism (12%), anemia (20%), diabetes mellitus (16%) and alopecia areata 
(7.4%) was reported in a comparative study also in India (Gopal et al. 2007). A 
hospital-based study from India demonstrated co-occurrence of vitiligo with 
skin associated autoimmune diseases like morphoea, alopecia areata, discoid 
lupus erythematosus, and pemphigus erythematosus (Poojary 2011). Halo nevi 
are described in up to 31% of the cases in vitiligo, they are more characteristic 
of children and young adults (van Geel et al. 2011c; Barona et al. 1995). In 
addition, familial vitiligo probands have demonstrated also higher prevalence of 
diabetes mellitus (3.3% vs 0.7%) and asthma (0.8% vs 0.4%) (Liu et al. 2005; 
Zhang et al. 2009). In the USA the members of “multiplex” vitiligo families had 
elevated frequencies of autoimmune thyroid disease (21.4% vs 1.9%), 
rheumatoid arthritis (3.8% vs 0.9%), psoriasis (5.3% vs 1%), adult-onset 
insulin-dependent diabetes (3.8% vs 0.6%), pernicious anemia (2.3% vs 0.2%) 
and Addison’s disease (0.3% vs 0.005%), but not alopecia areata (2.8% vs 
1.8%), than in general population (Laberge et al. 2005).  
In most studies familial cases of vitiligo stay between 8% and 36%, but 
cases have been varied from 3.4% to 74% in India (Handa and Kaur 1999; 
Gopal et al. 2007; Poojary 2011; Misri et al. 2009). In the USA the frequency 
of vitiligo among siblings of nonselected vitiligo probands is 6.1% and the fre-
quency of vitiligo among siblings of familial vitiligo probands is 38.9%; that 
shows clearly the heritable risk of non-Mendelian pattern in vitiligo (Laberge et 
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al. 2005). Family history has been more characteristic of generalized vitiligo, 
but in 11.5% of the cases of familial segmental vitiligo the clinical type of the 
relative was also the segmental vitiligo in Korea (Hann and Lee 1996). Auto-
immune diseases of close relatives of vitiligo have been reported in up to 46% 
of the cases in Italy (Amerio et al. 2010). Very high prevalence of autoimmune 
diseases among the siblings of vitiligo probands with other autoimmune 
diseases (41%) compared with the prevalence among the siblings of probands 
with only vitiligo (14%) has been demonstrated in the USA (Laberge et al. 
2005). In the USA the elevation of autoimmune thyroiditis, pernicious anemia, 
Addison’s disease, systemic lupus erythematosus and inflammatory bowel 
disease has been demonstrated in the first-degree relatives in vitiligo (Alhateeb 
et al. 2003). In familial cases of vitiligo the first-degree relatives have shown 
higher prevalence of chronic urticaria (0.6% vs 0.1%), rheumatoid arthritis 
(0.6% vs 0.3%) and psoriasis (0.2% vs 0.1%) in China (Zhang et al. 2009).  
 
 
2.2.2. The presence of APS and autoantibodies in vitiligo 
Vitiligo can be part of all types of autoimmune polyendocrine syndromes 
(APS), but most often it occurs with autoimmune thyroid disease (Hashimoto’s 
thyroiditis and Graves’ disease) in APS-3. A systematic review of published 
papers shows a median prevalence of 14.3% and a relative risk 2.5 of auto-
immune thyroid disease, 20.8% and 5.2 of the presence of thyroid-specific 
autoantibodies in patients with vitiligo compared with nonvitiligo subjects, and 
the risk seems to increase with age (Vrijman et al. 2012). Autoimmune thyroid 
disease has been the most frequently reported concomitant disease in children 
(5–24% ) and up to 34% in adults with vitiligo (Pagovich et al. 2008; Kurtev 
and Dourmishev 2004; Mason and Gawkrodger 2005). Usually vitiligo is the 
first disease of APS-3 and precedes autoimmune thyroid disease by 4–35 years 
(Zettinig et al. 2003; Betterle and Zanchetta 2003; Amerio et al. 2006, 2010). 
Thyroid antibodies have been detected in 18–50% of the cases of vitiligo in 
comparative studies of children and adults (Kurtev and Dourmishev 2004; 
Hegedus et al. 1994; Daneshpazhooh et al. 2006). Vitiligo occurs in 4.5–20% of 
the cases in APS-2 and 0–25% of the cases in APS-1 (Papadopoulos et al. 1990; 
Dittmar and Kahaly 2003; Perniola 2000; Myhere 2001). A study from Ger-
many has pointed out the most often combined autoimmune diseases in patients 
with APS: first type diabetes and autoimmune thyroid disease in 41%, AITD 
and Addison’s disease in 15%, first type diabetes and vitiligo in 10% and AITD 
and vitiligo also in 10% of the cases (Kahaly 2009). Thyroid autoimmune di-
sease, autoimmune gastritis and alopecia areata have been the most common 
autoimmune diseases associated with vitiligo in cases of APS-3 in Italy (Amerio 
et al. 2010). All other endocrine and nonendocrine autoimmune diseases com-
bined with vitiligo not classified under the first three types of APS, like alo-
pecia areata, rheumatoid arthritis, pernicious anemia, type 1 diabetes, bullous 
pemphigoid, can now be classified under APS type 4 (Betterle and Zanchetta 
2003; Amerio et al. 2010). 
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Autoantibodies have been detected in the range from 2% to 70% in different 
studies in vitiligo (Barona et al. 1995; Bystryn 1989). In addition to thyroid 
antibodies, there are several other antibodies detected in the sera of patients 
with vitiligo with widely variable results. Long follow-up of patients with APS 
has confirmed that “silent” autoantibodies may precede clinical manifestation of 
the disease 3–30 years and they are predictive for the development of auto-
immune disorder in the future (Dittmar and Kahaly 2003). Antimelanocyte anti-
bodies were detected in 31% of the cases and RF in 11% of the cases in vitiligo 
and the difference was statistically important compared with the controls in Iran 
(Farrokhi et al. 2005). In Germany the difference of antibodies against cell 
surface antigens of melanocytes was not shown between vitiligo and controls 
(Schallreuter et al. 1994). 
 
 
2.3. Quality of life and emotional state in vitiligo 
Pigment loss is not merely a cosmetic problem as it influences psychological 
and social well-being and impairs the quality of life. Patients with vitiligo have 
reported that healthcare professionals do not take their condition seriously 
(Ongenae et al. 2004). A survey among dermatologists in the Netherlands 
brought out that only 16% of the specialists had used treatment in vitiligo, most 
of them had simply provided information about the disease (Njoo et al. 1999). 
QoL studies allow us to better understand psychological and disease-related 
problems in vitiligo nowadays. More than a half of the respondents of the 
Vitiligo Society in the United Kingdom stated that vitiligo had moderately or 
severely affected their QoL (Talsania et al. 2010). Vitiligo does not cause 
notable physical impairment but affects human self-esteem in different ways: 
predisposes social isolation, depression, difficulties in sexual relationship and 
suitability for marriage (Mechri et al. 2006; Firooz et al. 2004; Wang et al. 
2011; Porter et al. 1990). People with dark skin colour are more stigmatised 
(Linthorst et al. 2009; Dolatshahi et al. 2008). QoL issues that arise from the 
loss of the pigment are the following: choice of clothes, use of sunblocks, use of 
camouflage, avoidance of activities; and negative reactions of others (Ongenae 
et al. 2005a,b; Tanioka et al. 2010; Porter 2000). Some studies have stressed 
psychiatric comorbidity in patients with vitiligo with the prevalence of 25–35% 
in Europe and in India (Kent and al-Abadie 1996; Picardi et al. 2000; Mattoo et 
al. 2001, 2002). Adjustment disorders have been revealed in more than half of 
the vitiligo cases in India, but it does not correlate well with the severity or 
extension of depigmentation (Mattoo et al. 2001, 2002). 
Many studies have used Dermatology Life Quality Index (DLQI) question-
naire for measuring the impact of QoL in vitiligo. DLQI was worked out by 
Finley and Khan in 1994 for assessment of QoL in patients with cutaneous 
diseases (Finlay and Khan 1994). DLQI has given widely variable results in 
vitiligo. DLQI has shown small effect on patients’ life in Indonesia (4.4), U.K 
(4.8) and Belgium (4.95) and moderate effect in Japan (5.9), Germany (7.0), 
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Iran (7.1–8.2), France (7.2) and China (8.4) (Chan et al. 2012; Kent and 
al-Abadie 1996; Ongenae et al. 2005b; Tanioka et al. 2010; Radtke et al. 2009; 
Dolatshahi et al. 2008; Aghaei et al. 2004; Mashayekhi et al. 2010; Kosto-
poulou et al. 2009; Wang et al. 2011). According to DLQI, the impact of 
vitiligo on QoL has been very large in India (10.7) and Saudi Arabia (14.7–
17.1) (Parsad et al. 2003; Al Robaee 2007; Al-Mubarak et al. 2011). Higher 
DLQI scores are associated with darker skin as the contrast of skin colour in 
dark-skinned people attracts more unwanted attention, which is emotionally 
disturbing and displeasing. A survey of Malaysian vitiligo patients has shown 
that the mean DLQI was not associated with gender or age or disease duration 
or family history of vitiligo (Wong and Baba 2012). Several studies have 
reported lower QoL in women, as they are more emotional and more sensitive 
about their appearance (Radtke et al. 2009; Mashayekhi et al. 2010; Belhadjali 
et al. 2007; Borimnejad et al. 2006). Comparative studies have pointed out that 
subjects with vitiligo are more disturbed in symptoms and feelings, leisure and 
daily activities (Wang et al. 2011; Ongenae et al. 2005b). Vitiligo has no impact 
on such activities like going to school or work, as pigment loss does not cause 
physical disability (Wang et al. 2011; Ongenae et al. 2005b; Radtke et al. 2009; 
Wong and Baba 2012). It affirms that subjects with vitiligo are embarrassed and 
do not feel free in dressing and spending time with other people as they have to 
choose clothes to hide skin imperfection. This group of patients (40%) belongs 
to the group of “poor adjustment” by the Porter, they have lower self-esteem 
and they experience difficulties in coping well with vitiligo (Porter et al. 1978, 
1979). Most studies have emphasized the association between disease extension 
and lower QoL (Wang et al. 2011; Dolatshahi et al. 2008; Ongenae et al. 
2005b; Parsad et al. 2003; Belhadjali et al. 2007; Ingordo et al. 2012). Vitiligo 
on uncovered areas like the face and hands has a serious negative impact on 
QoL, as stated by several investigators (Aghaei et al. 2004; Wong and Baba 
2012; Ingordo et al. 2012). Camouflage has decreased the mean DLQI score in 
women with vitiligo by 1–1.5 score-points and is highly suggested for those 




2.4. Etiopathogenesis of vitiligo.  
Neuroendocrine dysregulation in vitiligo 
2.4.1.  Etiopathogenesis of vitiligo 
The exact etiology and pathogenesis of vitiligo is still unknown. Scientists do 
not know the real cause of damage of melanocytes and their disappearance from 
affected skin as has been shown in immunohistological and ultrastructural 
studies. Experimental studies have supported several pathways how melano-
cytes can disappear: an apoptotic process, a necrotic process and melano-
cytorrhagy (van den Wijngaard et al. 2000a; Gauthier et al. 2003a,b; Le Poole 
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et al. 2004). According to the theory of melanocytorrhagy, melanocytes are 
weakly attached and a minor friction can induce upward migration and their 
loss (Gauthier et al. 2003a,b). There is also evidence that melanocytes are never 
completely absent in the lesional epidermis of vitiligo and they are able to 
recover their functionality even after long duration of the disease (Tobin et al. 
2000). Several pathophysiological hypotheses have been proposed to explain 
the dysfunction and/or loss of melanocytes in epidermis in vitiligo (Alikhan et 
al. 2011). These include an autoimmune hypothesis, biochemical hypothesis 
(auto-cytotoxicity and oxidative stress) and decreased melanocyte survival 
hypothesis (Ongena et al. 2003; Schallrauter et al. 1999a; Moretti et al. 2002; 
Lee et al. 2005a).  
Studies have confirmed the increase of autoimmune thyroid disease and 
several other autoimmune diseases in vitiligo probands and their close relatives, 
indicating the shared genetic etiologic links between vitiligo and these disorders 
(Alhateeb et al. 2003; Laberge et al. 2005; Zhang et al. 2009). Cellular immu-
nity is altered in vitiligo and it can be combined with a humoral response (Pas-
seron and Ortonne 2005; Alikhan et al. 2011). Immunohistological studies have 
shown an increase of CD8+ T cells and an increase of CD8/CD4 ratio of T cells 
in the perilesional skin in vitiligo (Le Poole et al. 1996; Lili et al. 2012). CD8+ 
T cells express the skin-homing cutaneous lymphocyte antigen, cytotoxic pro-
teins perforin and granzyme B, IL-2 (CD25), MHC II (HLA-DR), and they 
secrete IFN-γ, which increases ICAM-1 expression and promotes T cell 
migration to the skin (van den Wijngaard et al. 2000b; Sharquie et al. 2004; 
Badri et al. 1993; Wankowicz-Kalinska et al. 2003). Regulatory T cells that 
modulate Th1 and Th17 response are reduced in vitiligo skin and their function 
is impaired, that allows activation of cytotoxic T cells (Klarquist et al. 2010; 
Lili et al. 2012). Experimental studies in Smyth line chickens, an animal model 
of vitiligo, have shown melanocytes’ death via apoptosis induced by cytotoxic 
T lymphocytes (Wang and Erf 2004). Recently a mouse model with a pheno-
type of vitiligo has been developed by using melanocyte-specific CD8+ T cells 
(Harris et al. 2012).  
Auto-cytotoxic mechanism encompasses metabolic deregulation that can 
lead to toxic damage of the melanocytes (Hann and Chun 2000b). These toxic 
metabolites, derived from the environment (phenols or quinones) or produced as 
byproducts of altered melanin synthesis pathway, accumulate and damage 
melanocytes of genetically susceptible individuals (Schallreuter et al. 1994b). 
Increased level of 6-tetrahydrobiopterine (6BH4), a cofactor of phenylalanine 
hydroxylase, leads to an accumulation of byproducts 7BH4 and H2O2. Accu-
mulation of H2O2 in turn influences the increase of 6-biopterine that is cytotoxic 
for cells at high concentration (Schallreuter et al. 1999a; Schallreuter et al. 
2001). The disturbed biosynthesis of catecholamines has been under research in 
vitiligo as the patients with segmental vitiligo have shown the increase of 
catecholamines and their metabolites in the sera and urine (Morrone et al. 1992; 
Cucci et al. 2000, 2003). The high level of catecholamines may be directly 
cytotoxic to the melanocytes via oxidative stress caused by increased level of 
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dopamine, with the result of the apoptosis of melanocytes (Chu et al. 2006). 
Decreased level of catalase enzyme and increased level of H2O2 in the skin, but 
also defective calcium uptake can alter oxidative balance in vitiligo (Schall-
reuter et al. 1999a). Melanocytes at the margin of lesional skin have shown high 
sensitivity to oxidative stress in vitiligo (Koca et al. 2004; Jimbov et al. 2001). 
There is growing evidence that stressed melanocytes can initiate an immune 
response. The first proof of this hypothesis was the activation of dendritic cells 
after melanocytes damage by 4-tertiary butyl phenol exposure (Kroll et al. 
2005). Phenols can activate the unfolded protein response in melanocytes that 
leads to upregulation of IL-6 and IL-8 (Toosi et al. 2012). This upregulation 
could be the missing link between oxidative stress and immune response in 
vitiligo as it can reduce the modulation of regulatory T cells (Passeron and 
Ortonne 2012). Another experimental study has found that subtoxic levels of 
H2O2 could also stimulate secretion of IL-6 by cultured epidermal melanocytes 
and generate autoimmune response (Yao et al. 2012). 
The theory of decreased melanocyte survival hypothesis says that vitiligo 
can be caused by the abnormality of melanocytes or of surrounding keratino-
cytes-producing factors necessary for the survival and functioning of the 
melanocytes (Ongena et al. 2003; Moretti et al. 2002). The paucity of keratino-
cyte-derived stem cell factor influences also the synthesis of melanin and 
predisposes the apoptosis of melanocytes (Lee et al. 2005a). However, there 
exists a convergence theory that comprises the previously reported mechanisms 
and states that autoimmunity, mutations, stress, accumulation of toxic com-
pounds, altered cellular environments and impaired melanocyte migration all 
contribute to pathogenesis of vitiligo and it depends on the patient which 
mechanism dominates (Le Poole et al. 1993).  
 
 
2.4.2. Neuroendocrine dysregulation in vitiligo 
Dysfunction of the neural regulation has been shown in different autoimmune 
and inflammatory disorders. Dysregulation of the nervous system at central or 
local level may damage melanocytes also in vitiligo. The importance of central 
neuroendocrine system emerges at the onset or aggravation of pigment loss 
during or after increased stress period in vitiligo up to 62.5% of the cases 
(Firooz et al. 2004).  
The melanocortin system is a part of the neuroendocrine system that acts as a 
coordinator and executor of responses to stress. Melanocortin system consists of 
five melanocortin receptors (MCR1–MCR5), four agonists of these receptors 
[(α-, β- and γ- melanocyte-stimulating hormone (MSH) and adrenocorticotropic 
hormone (ACTH)] and two antagonists of melanocortin receptors: agouti 
(ASIP) and agouti-related protein (AGRP) (Gantz and Fong 2003). The com-





Figure 1. The components of the melanocortin system: POMC, proopiomelanocortin; 
ASIP, agouti signalling protein; α-MSH, alpha-melanocyte-stimulating hormone; 
b-MSH, beta-melanocyte-stimulating hormone; γ-MSH, gamma-melanocyte-stimu-
lating hormone; ACTH, adrenocorticotropic hormone; AGRP, agouti-related protein; 
MC1R, melanocortin receptor 1; MC2R, melanocortin receptor 2; MC3R, melanocortin 
receptor 3; MC4R, melanocortin receptor 4; MC5R, melanocortin receptor 5. 
 
 
α-, β-, γ- MSH and ACTH are the posttranslational products of POMC pro-
hormone gene. Posttranslational processing of the POMC prohormone is tissue 
specific (Pritchard et al. 2002). The expressional level of the peptides of the 
melanocortin system is highest in the brain, but it involves also peripheral 
tissues, including the skin (Kono et al. 2001; Pritchard et al. 2002). In the skin 
POMC mRNA has been detected in keratinocytes and melanocytes of the basal 
layer of epidermis and in pilosebaceous units (Kono et al. 2001). MC1R is the 
most highly expressed melanocortin receptor in melanocytes but expressed also 
in keratinocytes, fibroblasts, endothelial cells and antigen-presenting cells (Ro-
berts et al 2006). MC1R is activated mainly by α-MSH and ACTH, the acti-
vation is weak by β- and γ- MSH. The main function of MC1R is the regulation 
of melanogenesis, skin and hair pigmentation (Gantz and Fong 2003). MC2R is 
expressed mainly in adrenal cortex and adipocytes, to a lesser extent in skin, in-
cluding keratinocytes and melanocytes (Eves and Haycock 2010). This receptor 
is highly specific for ACTH and its main function is the regulation of steroido-
genesis (Getting 2006). MC3R is expressed in gastrointestinal tract, kidneys, 
heart, placenta and is activated by all the melanocortins but especially by γ- 
MSH (Chhaljani 1996; Eves and Haycock 2010). There are no previous studies 
















This receptor is strongly involved in energy homeostasis (Gantz and Fong 
2003). MC4R is predominantly expressed in CNS, to a lesser extent in dermal 
papilla cells. MC4R is activated mostly by α-MSH and ACTH. The binding of 
melanocortins with MC4R is similar to MC1R. MC4R regulates energy 
homeostasis and erectile function (Getting 2006; Bohm et al. 2006). MC5R is 
widespreadly expressed in many tissues, including adipocytes, sebaceous and 
sweat gland cells, skin mast cells (Chhaljani 1996; Slominski et al. 2000). 
MC5R has high affinity for α-MSH, lesser activated by ACTH and no affinity 
for γ- MSH (Gantz and Fong 2003). The main function of MC5R is the regu-
lation of sebaceous gland secretion (Zhang et al. 2006). ASIP and AGRP are 
two endogenous paracrine signalling molecules with MCR subtype selectivity 
(Dinulescu and Cone, 2000; Rana 2003). ASIP is highly expressed in adipo-
cytes but expression is also detected in many other tissues, including dermal 
papilla cells (Wilson et al. 1995). ASIP is high-affinity antagonist of α-MSH at 
MC1R that results in inhibition of cAMP mediated activation of melanogenesis 
(Slominski et al. 2000). ASIP is also a strong inhibitor of MC2R and MC4R 
(Dinulescu and Cone, 2000). AGRP is the second endogenous antagonist of 
melanocortin receptors that shares sequence homology with ASIP (Ollmann et 
al. 1997). AGRP is expressed mainly in the brain and adrenal tissue and it 
blocks the binding of α-MSH to MC3R and MC4R (Yang et al. 1999; Gantz 
and Fong 2003). The main function of AGRP is to control feeding and body 
weight (Adan and Gas 2003). Its action to melanogenesis in humans has not 
been verified yet. Melanocortin system is involved in determining skin and hair 
phenotypes, different skin inflammatory disorders and malignancies (Slominski 
et al. 1993; Sturm 2002). The studies have demonstrated a reduction in the level 
of the POMC peptide α-MSH both in the lesional skin and serum of vitiligo 
patients (Thody et al.1998; Pichler et al. 2006; Spencer et al. 2007). Low 
expression of α-MSH in the lesional skin of vitiligo patients has resulted from 
decreased expression of the peptide rather than a reduction in melanocyte 
numbers (Graham et al. 1999). Few studies have focused on analyzing con-
nections between vitiligo and polymorphisms of genes of melanocortin system. 
Na et al. could not prove the association between variations of MC1R and ASIP 
genes and susceptibility to vitiligo in Korean patients (Na et al. 2003). Szell et 
al. demonstrated in the Hungarian vitiligo patients that Arg160Trp MC1R poly-
morphism might have protective effect against vitiligo (Szell et al. 2008). There 
are no previous studies analyzing the mRNA ecxpression levels of the melano-
cortin system in group of vitiligo patients. 
Several different pathways are modulating the melanogenesis in humans. 
The most important pathway in human melanocytes through which signal from 
the melanocortin system reaches the melanogenesis enzymes tyrosinase (TYR), 
tyrosinase-related protein-1 (TYRP1) and dopachrome tautomerase (DCT) is 
the cyclic adenosine monophosphate/protein kinase A (cAMP/PKA) pathway, 
modulated by Wnt and mitogenactivated protein kinase (MAPK) pathways 
(deOliveira et al. 1996; Konda et al. 1994; Slominski et al. 2004). The melano-
cortin receptors activate adenylate cyclase giving rise to the intracellular cAMP 
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concentration and further activation of protein kinase A (Gantz and Fong 2003; 
Ao et al. 1998). Protein kinase A activates cAMP responsive element binding 
protein 1 (CREB1) through phosphorylation that increases the expression level 
of microphthalmia-associated transcription factor (MITF) (Sassone-Corsi 1998; 
Levy et al. 2006). MITF regulates positively the expression of TYR, TYRP1 
and DCT increasing the transcription of these enzymes (Levy et al. 2006; Park 
et al. 2002; Yasumoto et al. 1997). MITF is an important gene of melano-
genesis as it controls the differentiation of melanocytes. The studies have 
demonstrated that ectopic expression of MITF converts fibroblasts to the cells 
with melanocyte characteristics (Steingrimsson et al. 2004; Tachibana et al. 
1996). MITF up-regulates the expression of the antiapoptotic factor B-cell 
lymphoma 2 (BCL2), the deletion of MITF in melanocytes results in an exten-
sive apoptosis of these cells (McGill et al. 2002). Lymphoid enhancer-binding 
factor 1 (LEF1) is a transcription factor that participates in the Wnt signalling 
pathway (Eastman and Grosschedl 1999). LEF1 acts as a regulator of pig-
mentation in melanocytes, exerting its effects on MITF in two ways: it activates 
the transcription of the MITF gene and MITF can activate its own promoter 
together with LEF1 (Saito et al. 2002). The interaction of MITF and LEF1 also 
regulates the expression of DCT (Yasumoto et al. 2002). The upstream 
transcription factor 1 (USF1) belongs to the basic/helix-loop-helix/ leucine 
zipper (b-HLH-zip) family similarly with MITF (Corre and Galibert 2005). 
USF1 goes through phosphorylation by 38 kDa MAP kinase (p38) in melano-
cytes, binds to the promoter of TYR and activates its transcription regulating the 
pigmentation (Galibert et al. 2001). Promoter of DCT contains also the USF1 
binding element (Schwahn et al. 2005). Phosphoinositide 3-kinase (PI3K) 
regulates the cycle, growth, differentiation and apoptosis of the cells (Garcia et 
al. 2006). PIK3K has an influence to melanogenesis by inhibiting the activation 
of p38 in melanocytes (Saha et al. 2006). Phosphoinositide 3-kinase/70 kDa 
ribosomal protein S6 kinase (PI3K/p70(S6)K) has coded by the gene RPS6KB1 
and it participates in the regulation of translation, immune response and tissue 
reparation (Berven and Grouch 2000). Both kinases have an ambivalent effect 
on the melanogenesis pathways that depends on the concentration of the growth 
factors (Bohm et al. 1995). cAMP has an inhibitory effect on the PI3K/ 
p70(S6)K pathway (Busca et al. 1996). 
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3. AIMS OF THE STUDY 
The general aim of this study was to obtain additional knowledge in vitiligo as 
the main pigmentary disorder in humans. 
The specific aims of the study were: 
1. To observe clinical aspects and the presence of autoantibodies in vitiligo. 
2. To examine the impact of quality of life and emotional state in vitiligo and to 
compare these results with psoriasis patients and healthy volunteers. 
3. To elucidate the regulative role of the melanocortin system in pathogenesis 
of vitiligo, assessing the expressional level of mRNA of melanocortin 
system peptides and their receptors but also the gene expression profile of 
the intracellular signalling pathways linking the melanocortin system with 
enzymes involved in melanogenesis in the skin in vitiligo and healthy 
controls. 
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4. SUBJECTS AND METHODS 
4.1. Ethical considerations 
The Ethics Review Committee on Human Research of the University of Tartu 
approved the study protocols and the informed consent forms. All participants 
signed the written informed consent. 
 
 
4.2. Characteristics of the study participants 
Adult vitiligo patients (≥18 years) across the country were asked to participate 
in the study, which was advertised in the newspaper. Patients with vitiligo were 
also recruited from among the attendants of the outpatient department of 
Dermatology Clinic at Tartu University Hospital. Subjects with psoriasis were 
collected mainly from the inpatient department of the clinic and control subjects 
were enrolled from among the health care personnel, students and attendants 
who had been consulted in the clinic with benign skin tumours. All the subjects 
who had participated in the study were Estonian-speaking Caucasians.  
 
Table 2. Subjects’ characteristics in the published papers. 
Paper I Vitiligo 155 (44 M, 111 F)  
Mean age 44.9 years, age range 18–82 years 
141 tested for autoantibodies  
 
Paper II Familial vitiligo 51 (15 M, 36 F) 
Mean age 41.7 years, age range 18–82 years 
Sporadic vitiligo 135 (42 M, 93 F)  
Mean age 45.5 years, age range 18–77 years 
173 tested for autoantibodies  
 
Paper III Vitiligo 54 (22 M, 32 F), mean age 36.6 years 
Mean disease duration 11.3 years 
Psoriasis 57 (27 M, 30 F), mean age 40.0 years 
Mean disease duration 18.6 years 
Controls 57 (23 M, 34 F)  
Mean age 39.7 years 
 
Paper IV Vitiligo 31 (22 F, 9 M) 
Mean age 49.2 years, age range 22–75 years 
Type: focal 4 (F), segmental 1 (F), generalized 25 
(17 F, 8 M ), universal 1(M) 
Stage: active 22 (16F, 6M); stable 9 (6 F, 3 M)  
Mean disease duration: 19.2 years 
Controls 24 (17 F, 7 M)  
Mean age 33.9 years  
Age range 21–67 years 
 
Paper V Vitiligo 39 (26 F,13 M)  
Mean age 49.4 years, age range 22–77 years 
Type: focal 7 (5 F, 2 M), segmental 1 (F), 
generalized 30 (20F, 10M), universal 1 (M) 
Stage: active 26 (18 F, 8 M), stable 13 (8 F, 5 M) 
Mean disease duration: 19.0 years 
Controls (MITF-M, p38, 
PI3K, P70 (S6)K): 31 (22 F, 
9 M) Mean age 38.1 years  
Age range 22–67 years 
Controls (CREB1, BCL2, 
LEF1, USF1): 18 (10 F, 8 M)  
Mean age 37.6 years 
Age range 22–66 years 
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4.3. Methods 
4.3.1. Skin examination and disease status classification 
The patients were examined at the Dermatology Department of Tartu University 
by an experienced dermatologist. The diagnosis of vitiligo was based on charac-
teristic loss of skin pigmentation with typical localization and the examination 
under Wood’s lamp. Wood’s lamp is a device that helps better visualize pig-
ment changes in the epidermis. The clinical types of vitiligo were classified as 
focal (one or a few macules in a nondermatomal distribution), segmental (unila-
teral segmental distribution), acrofacial (distal parts of the extremities and face), 
vulgaris (scattered over the body), universal (over 90% depigmentation). The 
palm method was used by calculating body surface area (BSA). The presence of 
leukotrichia, the Koebner phenomenon and halo nevi was noted. The evolution 
of vitiligo was considered active when new lesions appeared and the existing le-
sions had increased in size over the past 3 months. Vitiligo was considered 
stable when depigmentation had not increased during the last 3 months. Skin 
phototype, based on classification by Fitzpatrick, was determined (Fitzpatrick et 
al. 1967). Psoriasis area and severity index (PASI) was used in cases of 
psoriasis. 
 
4.3.2. Data collection 
Five different questionnaires were used for data collection in the study. The 
questionnaire about demographic and clinical data, including age, sex, natio-
nality, skin phototype, site of onset of vitiligo, duration, the Koebner pheno-
menon, leukotrichia, mucous involvement, triggering factor, sunburn, mechani-
cal trauma, concomitant disease, familial history of vitiligo, spontaneous repig-
mentation, previous treatment, diseases in the family, was completed by a 
dermatologist in cases of vitiligo. The same questionnaires without vitiligo- 
specific questions were used for healthy controls and psoriasis patients. Derma-
tology Life Quality Index (DLQI) questionnaire validated Estonian version was 
implemented to calculate the impact on quality of life of all the study subjects 
(Finley and Khan 1994). Ten items (Q1-2 symptoms and feelings, Q3-4 daily 
activities, Q5-6 leisure, Q7 work/school, Q8-9 personal relationships, Q10 treat-
ment) were answered in DLQI questionnaire in a short time on four-point scale 
(0–3) with the sum of the score from 0 to 30. Emotional State Questionnaire 
(ES-Q) validated Estonian version was applied to assess the traits of depression 
and anxiety (Aluoja et al. 1999). ES-Q contains 28 items and is answered on a 
five-point scale (0–4). Eight items (sadness, loss of interest, inferiority, self- 
accusation, hopelessness about future, thought of suicide, feeling of loneliness 
and inability to be joyful) with cut-off score 12 was used for depressiveness; six 
items (fast irritation or getting angry, anxiety or fear, feeling of stress or inabi-
lity to relax, too much worry about many things, physical restlessness and being 
very easily frightened) with cut-off score 12 for general anxiety; five items 
(sudden attacks of panic with palpitation, lack of air, feeling of fainting or other 
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frightening physical symptoms; fear to be alone away from home; fear of public 
places or streets; fear to faint among crowd; fear to be on a bus, tram, train or 
car) with cut-off scores 7 for panic disorder; two items (fear to be centre of 
attention, fear to communicate with strangers) with cut-off scores 4 for social 
phobia; four items (passivity or fatigue, decreased ability to concentrate or to 
pay attention, rest does not give strength; and fast tiredness) with cut-off scores 
6 for asthenia; three items (difficulties in falling asleep, restlessness or frag-




4.3.3. The assessment of autoantibodies 
14 ml blood was collected once for the detection of TPO-Ab, PCA, ANA, AAA 
and RF in the sera. The autoantibodies assessment was performed in the United 
Laboratories at Tartu University Hospital. ANA, PCA and AAA were 
determined by indirect immunofluorescence method, using rat liver as an 
antigenic substrate for ANA and mouse stomach as and antigenic substrate for 
the detection of PCA. AAA was detected on normal human adrenal tissue (Uibo 
et al. 1998; Betterle et al. 2007). Polyclonal rabbit anti-human IgG conjugated 
to fluorescein isothiocyanate (DAKO, Glostrup, Denmark) was used as a 
secondary antibody for the detection of all these antibodies. CLIA, Immulite 
2000 (Siemens Medical Solutions Diagnostics) was used for the detection of 
TPO-Ab) and immunoturbidimetric assay, Cobas Integra 400 Plus (Roche 
Diagnostics GmbH) for the assessment of RF (Laulu et al. 2007). 
 
 
4.3.4.  Collection of skin samples 
Two skin biopsies (Ø 4 mm) were obtained from each patient with vitiligo: one 
from the central part of involved skin and another from the non-sun-exposed 
uninvolved skin. One skin biopsy (Ø 4 mm) from nonsun-exposed skin was 
taken from healthy control subjects. The non-sun-exposed skin was defined as 
the skin never exposed to ultraviolet radiation (UVR) previously and definitely 
not exposed to natural UVR in the last 12 months. Biopsies from uninvolved 
skin of vitiligo patients and healthy controls were taken from the lower ab-
domen or inner side of the upper arm. Biopsies were instantaneously snap- 
frozen in liquid nitrogen and stored at -80 ºC until further use.  
 
 
4.3.5. Complementary deoxyribonuclein acid (cDNA) synthesis 
Total ribonuclein acid (RNA) was isolated from tissues using RNeasy Fibrous 
Tissue Mini Kit (QIAGEN Sciences, MD, USA) following the protocol sug-
gested by the manufacturer. For tissue homogenization, Ultra-Turrax T8 homo-
genizer (IKA Labortechnik, Germany) was used. RNA was dissolved in RNase 
free water and stored until further use at -80 ºC. For each RT-PCR reaction,  
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500 ng of total RNA were converted into cDNA. The reverse transcription 
reactions were performed with a reverse transcriptase (SuperScript III; Invitro-
gen Corp., Carlsbad, CA, USA) and poly (T18) oligonucleotides in accordance 
with the manufacturer’s instruction. The reaction mixtures were incubated at  
65 ºC for 5 min, at 0 ºC for 1 min, at 50 ºC for 90 min, at 70 ºC for 5 min and 
finally stored at -80 ºC. 
 
 
4.3.6. Quantitative reverse transcriptase-polymerase  
chain reaction (QRT-PCR) 
Gene expression levels were detected in the ABI Prism 7900HT Sequence 
Detection System (Applied Biosystems, Foster City, CA, USA). Reactions were 
carried out in 10 ml reaction volumes in four replicates. The expression levels 
of genes under the study were detected applying TaqMan-QRT-PCR method 
using TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, 
CA, USA). For the detection of the expression levels of studied genes we used 
TaqMan Assay-On-Demand FAM-labelled MGB-probe gene expression assay 
mixes (20X, Applied Biosystems, Foster City, CA, USA). 
The assay mixes used were Hs00361403_g1 (AGRP), Hs00181770_m1 (ASIP), 
Hs00252036_s1 (MC3R), Hs00271877_s1 (MC4R), Hs00271882_s1 (MC5R), 
Hs00167051_m1 (TRP1) and Hs00157244_m1 (DCT). Hs00165156_m1 (MITF), 
Hs00178872_m1 (PIK3CB), Hs00177357_m1 (RPS6KB1), Hs00176247_m1 
(MAPK14), Hs00231713_m1 (CREB1), Hs00273038_m1 (USF1), Hs00608023_ 
m1 (BCL2), Hs00212390_m1 (LEF1). For the detection of the expression levels of 
MC1R and MC2R, we used gene-specific primers (MC1R: forward 5’-TGCGGCT 
GCATCTTCAAG-3’, reverse 5’- TGATGGCATTGCAGATGATGA-3’; MC2R: 
forward 5’-CTCGATCCCACACCAGGAA- 3’, reverse 5’-TGTGATGGCCCC 
TTTCATGT-3’) and MGB-labelled probe (MC1R: FAM-TTCAACCTCTTTCTC 
GCC-NFQ; MC2R: FAM-TCT CCACCCTCCCCAGA-NFQ). For the detection of 
hypoxanthine phosphoribosyl-transferase-1 (HPRT-1) expression level, gene- 
specific primers (HPRT-1 exon 6, 5’-GACTTTGCTT TCCTTGGTCAGG-3’; 
HPRT-1 exon 7, 5’-AGTCTGGCTTATATCCAACACTTCG-3’; final concent-
rations 300 nM) and VIC-TAMRA-labelled probe (VIC-5’-TTTCACCAG 
CAAGCTTGCGACCTTGA-3’- TAMRA; final concentration 200 nM) were used. 
The expression level of POMC was detected using qPCR Core Kit for SYBR Green 
I (Eurogentec, Seraing, Belgium) and gene-specific primers (forward 
5’-CTACGGCGGTTTCATGACCT-3’, reverse 5’-CCCTCACTCGCCCT 
TCTTG-3’, final concentrations 100 nM). Gene expression analysis was performed 





4.4. Statistical analysis 
Standard chi-square analysis was used for finding differences in comparing 
study subgroups of vitiligo. In analyzing quality of life the data following 
normal distribution were parametrically tested by unpaired t-test and the data 
not following the normal distribution by Mann-Whitney t-test. For quanti-
fication of mRNA expression of genes of melanocortin system comparative 
cycle threshold (Ct) method (δCt value) was used, where the amount of target 
transcript was normalized according to the level of endogenous reference 
HPRT-1. Adjustment to normal distribution was tested by the Kolmogorov-
Smirnov test. The distribution of measurements of gene expressions by the 
applied method did not follow a Gaussian distribution; therefore Mann-Whitney 
U-test and Kruskal-Wallis test were used to test for differences between the 
groups. Correlation analysis was used to investigate relations between two para-
meters of one group. For measure of correlation the Spearman rank correlation 
was applied.  
For statistical analysis Microsoft Office 2008 Excel (Microsoft Corporate, 
Redmond, WA, USA) and GraphPad Prism 4 software (GraphPad Software, 
San Diego, CA, USA) were applied. P-values were calculated for each variable. 
Significance was defined as a probability value less than 0.05. 
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5. RESULTS 
5.1. Clinical aspects and the presence  
of autoantibodies in vitiligo  
Clinical aspects of vitiligo were observed in 155 patients, 44 males (28.4%) and 
111 females (71.6%). The mean age of the patients was 44.9 ± 16.3 years (age 
range 18–82 years) and the mean age of vitiligo onset was 28.5 ± 17.2 years 
(age range 2–76 years). There were no statistically important differences in the 
onset of vitiligo and disease duration between the males and females (P = 0.733 
and P = 0.295, respectively). The mean age of onset for males was 28.2 ± 15.5 
years and for females 28.6 ± 17.9 years. The mean duration of vitiligo was  
16.9 ± 13.5 years (0.5–58 years) for all patients, 16.2 ± 14.6 years for males and 
17.2 ± 13.1 years for females. Age distribution of onset of vitiligo by the gender 




Figure 2. Distribution of the age of onset of females and males in vitiligo. 
 
 
According to skin phototypes by Fitzpatrick, 51 subjects (32.9%) had skin 
phototype II, 102 subjects (65.8%) had skin phototype III and 2 subjects (1.3%) 
had skin phototype IV. Vitiligo vulgaris was the most common clinical type, 
observed in 126 cases (81.3%), followed by acrofacial, focal, segmental and 
universal vitiligo. The patients with segmental and universal vitiligo were 
affected earlier than those with other types of vitiligo. The comparison of the 
ages of onset in different subtypes of vitiligo revealed statistically important 
difference between segmental and acrofacial type (P < 0.001), segmental and 
focal type (P < 0.05), segmental and vulgar type (P < 0.05), universal and acro-
facial type (P < 0.05) (Table 3).  
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Table 3. Mean ages of onset of vitiligo in the patients’ groups with different clinical 
subtypes 
Clinical subtype Number (M/F) (%) 
Mean age (y)  
of the onset of vitiligo 
Vulgaris 126 (30/96) (81.3) 28.0 
Universal 5 (2/3) (3.2) 14.6 
Acrofacial 12 (9/3) (7.7) 44.2 
Segmental 5 (1/4) (3.2) 7.6 
Focal 7 (2/5) (4.5) 34.7 
Total 155 (44/111) (100) 28.5 
 
 
Pigment loss started from the upper limb in 55 subjects (35.5%), followed by 
trunk/body folds in 50 (32.3%), lower limb in 27 (17.4%) and head/neck in 23 
(14.8%) subjects. Twenty patients (12.9%) showed the Koebner phenomenon. 
At the time of examination the disease was active and progressed in 109 
(70.3%) subjects, who confirmed appearance of new lesions or increase in the 
size of existing lesions within the past 3 months. 23 subjects (14.8 %) reported 
transformation of the initial clinical type of vitiligo. Vitiligo vulgaris was the 
initial clinical subtype in 113 subjects (72.9%) and five of them developed 
universal vitiligo. In 12 cases of focal vitiligo and 6 cases of acrofacial vitiligo 
the disease had transformed to vitiligo vulgaris. Segmental vitiligo did not 
transform to another subtype. Female gender was associated with increased risk 
of developing vulgar vitiligo (P = 0.008) and male gender of acrofacial vitiligo 
(P = 0.0002) (Table 3). In 82 cases (52.9%) up to 10% of body surface area was 
involved. BSA over 10% was associated with a higher risk of onset of vitiligo 
earlier, up to 20 years (P = 0.026). Pigment loss over 10% was statistically more 
prevalent in females comparing to males (P = 0.006). Leukotrichia was ob-
served in 75 cases (48.4%) and mucosal involvement in 14 cases (9.0%). 54 
patients (34.8%) had gone through a short-term treatment without any notable 
effect. During the course of vitiligo 43 subjects (27.7%) had noticed partial and 
unstable spontaneous repigmentation in some of their lesions.  
60 subjects (38.7%) named the factors that had brought on their vitiligo 
initially or worsened it. Both psychological stress and mechanical trauma were 
reported in 15 cases, followed by hormonal changes in 13 cases, sunburn in 6 
cases, UVR or radiation in 6 cases, skin irritation in three cases, drug intake in 
three cases, and another disease in one case. The presence of triggering factor 
was statistically significantly associated with female gender (P = 0.003). Addi-
tionally, the subjects with pigment loss over 10% of BSA associated onset and 
exacerbation of the disease statistically more often with the triggering factor  
(P = 0.0001). 79 subjects (51.0%) had suffered from severe sunburn during their 
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life without significant difference between genders, but the reported mechanical 
traumas were statistically more often associated with male gender (P = 0.041). 
In all, 104 subjects (67.1%) self-reported a concomitant disease and 57 of 
those (36.7%) had one or more diseases of autoimmune origin. Halo nevi were 
seen in 24 cases (15.5%); all but three had vitiligo vulgaris. In 9 cases (5.8%) 
halo nevi had anteceded to vitiligo. Personal history of thyroid disease was 
reported by 26 subjects (16.8%) and in 20 of those autoimmune thyreoiditis had 
been diagnosed. Other coexisting diseases are shown in Table 4. Female gender 
was associated with the increased risk of presence of concomitant autoimmune 
disease (P = 0.011) and autoimmune disease in the family (P = 0.042). Family 
history of vitiligo was positive in 40 cases (26.0%), thyroid disease in 32 
(20.8%), diabetes in 21 (13.6%), psoriasis in 13 (8.4%), rheumatoid arthritis in 
7 (4.5%) and hypertonia in 53 (34.4%) (Table 4). 
 
 
Table 4. Vitiligo associated diseases. 
Associated diseases Number (%)  
of vitiligo subjects 
with the disease 
Number (%) of 
vitiligo subjects 
whose relative  
has the disease 
Halo nevus 24 (15.5) 2 (1.3) 
Thyroid disease 28 (16.8) 32 (20.8) 
Diabetes 6 (3.9) 21 (13.6) 
Rheumatoid arthritis 6 (3.9) 7 (4.5) 
Psoriasis 7 (4.5) 13 (8.4) 
Gastroduodenal ulcer 2 (1.3) 0 
Pernicious anemia 2 (1.3) 0 
Alopecia areata 2 (1.3) 2 (1.3) 
Ankylosing spondylitis 2 (1.3) 0 
Multiplex sclerosis 1 (0.6) 0 
Sclerodermia 1 (0.6) 1 (0.6) 
Neurofibromatosis 1 (0.6) 0 
Addison disease 0 1 (0.6) 
Urticaria 8 (5.2) 0 
Fast type allergy (hair, dust, pollen) 7 (4.5) 1 (0.6) 
Asthma 5 (3.2) 3 (1.9) 
Atopic dermatitis 2 (1.3) 0 
Drug allergy 14 (9.0) 0 
Oncological, hematological disease 8 (5.2) 3 (1.9) 
Hypertonia 24 (15.5) 53 (34.4) 
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The levels of certain autoantibodies (TPO-Ab, PCA, ANA, AAA and RF) were 
measured in 141 subjects and the test proved positive in 70 cases (49.6%). 
Detected antibodies are shown in Table 5. Females showed statistically more 
positive blood tests of autoantibodies (P = 0.045), especially of TPO-Ab (P = 
0.013) as compared to males.  
 
 
Table 5. The presence of autoantibodies in the blood 
Autoantibodies type Number  
of vitiligo subjects,  
(M/F) 
% of vitiligo  
subjects 
TPO-Ab 52 (9/43) 36.9 
PCA 20 (4/16) 14.2 
AAA 4 (1/3) 2.8 
ANA 4 (1/3) 2.8 
RF 11 (4/7) 7.8 
 
 
According to the newest classification of APS by Betterle, several APS types 
were discovered and are shown in Table 6. APS cases were statistically more 
often discovered in females comparing to males (P = 0.007). 
 
 
Table 6. APS types in vitiligo. 
Type of APS Associated disease No of 
subjects 
APS-3 C 
APS-3 C (potential) 
APS-3 C + A 




Autoimmune thyroiditis, multiplex sclerosis, diabetes 









Differences between familial and sporadic cases of vitiligo were explored in 
186 patients, 51 of them were familial cases (15 M, 36 F, average age 41.7 ± 
15.6 years) and 135 sporadic ones (42 M, 93 F; average age 45.5 ± 16.3 years). 
In 173 of those the levels of TPO-Ab, PCA, ANA, AAA and RF were mea-
sured. In 67% of the familial cases, the subject had one relative with vitiligo, in 
33% two or more. The average age of the onset of vitiligo was 24.8 years ± 17.5 
(age range 3–76 years) in the familial group and 30.0 ± 16.5 years (age range 2–




Figure 3. Distribution of ages of the onset in familial (n=51) and sporadic (n=135) 
cases of vitiligo. 
 
 
The risk of the onset of the disease at the age up to 20 years was higher in the 
familial group (P = 0.008, OR 2.407, 95%CI 1.246–4.649). The patients in the 
familial group showed more widespread depigmentation compared with 
sporadic cases (BSA > 10%: P = 0.004, OR 2.606, 95% CI 1.341–5.064 and 
BSA > 50%: P = 0.001, OR 3.856, 95%CI 1.597–9.310; respectively). The 
distribution of the clinical subtypes of vitiligo was similar between the familial 
and sporadic vitiligo groups, as shown in Table 7. However, clinical subtype of 
vitiligo vulgaris at the onset of the disease was significantly associated with 
familial vitiligo (P = 0.008, OR 2.966, 95%CI 1.289–6.821).  
 
 
Table 7. Comparison of clinical subtypes of onset and at the time of examination in the 
groups of familial and sporadic vitiligo. 
 Number of the subjects (%) P value 
Clinical subtype at the onset Familial 
vitiligo 
Sporadic vitiligo  
Vitiligo vulgaris 43 (84%) 87 (65%) 0.008* 
Focal vitiligo 5 (10%) 26 (19%) 0.23 
Segmental vitiligo 1 ( 2%) 4 ( 3%) 0.706 
Acrofacial vitiligo 2 ( 4%) 18 (13%) 0.065 
Clinical subtype at the examination 
Vitiligo vulgaris 46 (90%) 107 (79%) 0.082 
Focal vitiligo 0 ( 0%) 9 ( 7%) 0 
Segmental vitiligo 1 ( 2%) 5 ( 4%) 0.548 
Acrofacial vitiligo 1 ( 2%) 11 ( 8%) 0.125 
Universal vitiligo 3 ( 6%) 3 ( 2%) 0.207 
* P value < 0.05 
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The patients with family history of vitiligo had darker skin types (types III–IV),  
(P = 0.045, OR 2.139, 95% CI 1.007–4.543). Familial vitiligo patients with 
widespread eruption (BSA > 50%) had higher risk for leukotrichia, mucosal 
depigmentation and the presence of triggering factors. Family history of vitiligo 
was not associated with concomitant autoimmune diseases. Thyroid disease was the 
most common autoimmune disease and 61 TPO positive subjects were found in the 
whole vitiligo group. Moreover, thyroid disease among relatives was reported 
higher in familial group comparing with sporadic cases (P = 0.03, OR 2.200, 95% 
CI 1.064–4.548). Nevertheless, when the frequency of concomitant diseases, 
autoimmune diseases and positive autoantibody findings between familial and 
sporadic vitiligo patients were compared, statistically significant differences 
between the groups were not found. In sporadic cases, female gender and disease 
duration of 10 years and longer were a risk factor for more extensive depig-
mentation (BSA > 10%: P = 0.001, OR 3.984, 95% CI 1.668–9.520 and P = 0.001, 
OR 3.560, 95% CI 1.681–7.539; respectively). Very extensive depigmentation, 
BSA > 50%, was associated with reported triggering factors (mechanical injury, 
psychological stress, hormonal changes, sunburn, radiation, skin irritation, drug 
intake and another disease) both in familial (P = 0.0005, OR 10.560, 95% CI 2.451–
45.497) and sporadic (P = 0.004, OR 7.630, 95% CI 1.580–36.858) cases. BSA > 
50% was also a risk factor for mucosal involvement both in familial (P = 0.01, OR 
8.000, 95% CI 1.261–50.772) and sporadic (P = 0.004, OR 7.375, CI 1.550–
35.096) groups. The association between widespread depigmentation (BSA > 50%) 
and leukotrichia was witnessed in both groups, but statistical difference was 
significant in familial group (P = 0.0001; OR 26.923, 95% CI 3.178–228.060). The 
patients with sporadic vitiligo with BSA > 50% had higher risk for serological 
autoantibody findings (P = 0.03, OR 4.941, 95%CI 1.005–24.300), especially the 
presence of PCA and ANA antibodies (P = 0.04; OR 4.457; 95%CI 0.994–19.978 
and P = 0.0002; OR 28.250; 95%CI 2.307–345.989 respectively) (Table 8). 
 
 
Table 8. The association of widespread pigment loss (BSA > 50%) with a triggering 
factor, leukotrichia, mucosal involvement and autoantibodies positivity in the groups of 
familial and sporadic vitiligo.  
 










8 0.001 10.560 9 0.004 7,630 
Leukotrichia 12 0.001 23.077 8 0.079 3.238 
Mucosal 
involvement 
4 0.014 8.000 3 0.004 7.375 
TPO-Ab 6 0.302 2.000 4 0.712 1.282 
PCA 1 0.371 0.377 3 0.04 4.457 
ANA 0   2 0.0002 28.250 
AAA 0   1 0.317 3.0556 
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5.2. Quality of life and emotional state in vitiligo 
compared with psoriasis and healthy volunteers 
The study group consisted of 54 subjects with vitiligo (32 F, 22 M; mean age 
36.6 ± 15.0; mean disease duration 11.3 ± 9.8 years), 57 subjects with psoriasis 
(30 F, 27 M; mean age 40.0 ± 13.3; mean disease duration 18.6 ± 12.7 years) 
and 57 unaffected controls (34 F, 23 M; mean age 39.7 ± 12.8 years). All the 
subjects were Caucasians with skin phototype I–IV (vitiligo: 17-II, 36-III, 1-IV; 
psoriasis: 1-I, 23-II, 33-III; healthy controls: 28-II, 28-III, 1-IV). The total mean 
DLQI score in vitiligo was 4.7 (ranges 0–22), which is statistically significantly 
higher from 0.6 (ranges 0–5) in healthy controls (P < 0.001) and statistically 
significantly lower from 13.1 (ranges 1–30) in psoriasis (P < 0.001). Based on 
the interpretation of the results of DLQI scale, no impairment of QoL was found 
in nine (16.7%) cases of vitiligo and in four (7%) cases of psoriasis, small 
impairment of QoL in 29 (53.7%) and in 10 (17.5%), moderate impairment of 
QoL in 12 (22.2%) and in 11 (19.0%), large impairment of QoL in three (5.6%) 
and in 20 (30%), a very large impairment of QoL in one (1.9 %) and in 12 
(21%), respectively (Figure 4). 
 
 
Figure 4. The percentage of the subjects with vitiligo, psoriasis and healthy controls who 
answered the DLQI questionnaire on the scale from “no effect” to “very large effect“. 
 
 
Vitiligo has highly significant impact on patients’ QoL on the scale of symptoms 
and feelings (P < 0.001), daily activities (P < 0.001), leisure (P < 0.001), but also 
treatment (P < 0.01) and personal relationships (P < 0.05), compared with the 
healthy volunteers. The subjects with psoriasis showed higher mean score in 
every evaluated DLQI item, compared with healthy controls and with vitiligo, and 





Figure 5. The data of mean scores on DLQI items scale in the group of vitiligo, the 
group of psoriasis and the group of healthy controls. 
 
 
The highest individual mean scores in vitiligo were obtained in Q4 (clothing 
1.07), Q2 (feelings 0.98) and Q5 (leisure 0.63). Female gender was associated 
with higher DLQI score in symptoms/feelings (P = 0.003) and male gender in 
relations (P = 0.040). In vitiligo the total DLQI was associated with disease 
activity (P = 0.006), disease extension (BSA ≤ 10% vs > 10%; P = 0.005), 
depigmentation of the hands (P = 0.008); and earlier disease onset (≤ 20 vs > 20 
years; P = 0.040). The total DLQI was not influenced by the gender, age, 
disease duration, pigment loss on other parts of the body, previous treatment, 
family history of vitiligo and concomitant diseases in the subjects with vitiligo. 
The total DLQI mean score was the highest (6.1) in the age group of 40–49 
years. In psoriasis DLQI was associated with the severity of the disease (PASI ≤ 
10 vs ≥20; P = 0.027) and concomitant arthritis (P = 0.019). Nail involvement 
did not show statistically significant effect (P = 0.062) on QoL. In the subjects 
with psoriasis DLQI was not associated with the gender, age, disease duration 
and family history of psoriasis. 
The analysis of ES-Q item scale did not reveal any statistically significant 
differences on the mean score of depression, general or social anxiety, panic, 
asthenia and insomnia in vitiligo compared with healthy controls shown in 
Figure 6. The subjects with psoriasis showed statistically higher scores on ES-Q 
item scale in depression (P < 0.05), general anxiety (P < 0.01) and asthenia (P < 
0.05), compared with vitiligo. The comparison between psoriasis and healthy 
controls accentuated statistically important difference in every item: depression 
(P < 0.001), general anxiety (P < 0.001) and insomnia (P < 0.001) but also panic 





Figure 6. The data of mean scores on Emocional State Questionnaire (ES- Q) items 
scale in the group of vitiligo, the group of psoriasis and the group of healthy controls. 
 
 
In spite of that, cut-off score of depression was found in 20% and general 
anxiety in 22% of the subjects with vitiligo, respectively. The subjects with 
depression symptoms scored higher on DLQI scale compared with undepressed 
vitiligo subjects (7.18 vs 4.19, P < 0.05) and had got vitiligo earlier in their life 
(mean age 18.1 vs 27.1). Even more, based on the cut-off score, 41% of the 
cases of vitiligo had asthenia with fatigue, 30% had sleep disturbances, 7% had 
social phobia and 2% had symptoms of panic disorder. 
 
 
5.3. Gene expression analysis  
of the melanocortin system in vitiligo  
Gene expression levels of POMC, the five melanocortin receptors (MC1R- 
MC5R) and endogenous melanocortin receptor antagonists (ASIP and AGRP) 
were measured by quantitative reverse transcriptase-polymerase chain reaction 
(QRT-PCR) in punch biopsies from the lesional and non-lesional skin of the 
vitiligo patients (n = 31) and from the non-sun-exposed skin of healthy subjects 
(n = 24). The levels of two genes encoding enzymes concerned with melano-
genesis – tyrosinase-related protein-1 (TRP1) and dopachrome tautomerase 
(DCT) – were measured.  
The presence of mRNA expression of examined genes in the skin of healthy 
controls and vitiligo patients became evident in QRT-PCR with a relatively 
large number (27–36) of amplification cycles. In the skin samples, MC1R 
demonstrated the highest expression (amplification after 27 cycles), whereas the 
levels of MC2R, MC3R, MC4R and MC5R mRNAs were low (amplification 
after 32–36 cycles) (Figure 7, Kingo et al. 2007). POMC mRNA was detected 
at 28–32 cycles, ASIP and AGRP became evident at 34–36 cycles. TRP1 and 




Figure 7. MC1R, MC2R, MC3R, MC4R and MC5R mRNA levels (relative to house-
keeping gene HPRT mRNA level) in the skin from healthy controls (HCS). 
 
 
Statistically significant differences in the expression of MC1R and MC4R 
between the healthy controls and vitiligo patients were found. The expression of 
MC1R mRNA was 1.6 fold higher in the non-lesional skin of vitiligo patients 
when compared to the healthy subjects (p < 0.01) (Fig. 8a, Kingo et al. 2007). 
The expressional level of MC4R in the non-lesional skin of vitiligo was 1.9 fold 
higher than in the healthy skin (p < 0.01) (Fig. 8b, Kingo et al. 2007). In the 
lesional skin 2.1 fold decrease of MC1R (p < 0.0001) and 2.5 fold decrease of 
MC4R (p < 0.01) expressions were detected when compared to the non-lesional 
skin samples from the patients with vitiligo (Fig. 8a,b, Kingo et al. 2007). The 
mRNA expression levels of the three other melanocortin receptors (MC2R, 
MC3R and MC5R) were also increased in the unaffected skin and decreased in 
the lesional skin of the vitiligo patients but these differences were not 
statistically significant (data not shown).  
A difference in POMC mRNA expression level, marginally satisfying the 
standard criteria of statistical significance (p < 0.05), was evident between the 
lesional and non-lesional skin of the vitiligo subjects (data not shown). The 
POMC mRNA expression was 1.9 fold lower in the depigmented skin com-
pared with the uninvolved skin in the vitiligo group. No significant differences 






Figure 8. MC1R (a) and MC4R (b) mRNA levels (relative to housekeeping gene HPRT 
mRNA level) in the skin from healthy controls (HCS), the non-lesional vitiligo skin 
(NLS) and the lesional vitiligo skin (LS).  
Bars indicate mean _ S.E.M. **p<0.01 compared to the healthy controls; ++ p < 0.01, 
+++ p < 0.0001 compared to the non-lesional skin. 
 
 
Suppression of TRP1 and DCT expressions in the lesional skin compared to the 
non-lesional vitiligo skin and healthy controls was established. To be more 
exact, 6.8 fold decrease of TRP1 mRNA expression in the involved skin 
compared with the skin of healthy subjects (p < 0.0001) and 19.7 fold decrease 
of TRP1 in the lesional skin compared to the uninvolved skin in the vitiligo 
group (p < 0.0001), was detected (Fig. 9a, Kingo et al. 2007). The expression of 
DCT mRNA was 7.6 fold lower in the involved skin of vitiligo compared with 
the skin of healthy controls (p < 0.0001) and 12.9 fold lower in the lesional skin 
compared to the uninvolved skin in the vitiligo group (p < 0.0001) (Fig. 9b, 
Kingo et al. 2007). Contrarily, the expression of TRP1 mRNA was 2.9 fold 
higher in the unaffected skin of the vitiligo patients compared to the healthy 
controls (p < 0.05) (Fig. 9a, Kingo et al. 2007). The expression level of DCT in 
the non-lesional skin of the vitiligo patients showed also a tendency of increase 
when compared to the healthy subjects but this finding was not statistically 





Figure 9. TRP1 (a) and DCT (b) mRNA levels (relative to housekeeping gene HPRT 
mRNA level) in the skin from the healthy controls (HCS), the non-lesional vitiligo skin 
(NLS) and the lesional vitiligo skin (LS).  
Bars indicate mean _ S.E.M. *p<0.05, ***p <0.0001 compared to the healthy control; 
+++ p <0.0001 compared to the non-lesional skin.  
 
 
Possible interactions between the expressions of the studied genes were exa-
mined by the Spearman rank correlation. In our previous study we had mea-
sured the expression of tyrosinase (TYR), an essential enzyme in melanin 
synthesis (Kingo et al. 2006). In addition to this, the correlations between the 
expressions of the genes of the melanocortin system and TYR were examined. 
TYR expression was elevated in the uninvolved vitiligo skin compared to the 
skin samples from controls, but the difference was not statistically significant. 
The data of the correlations between the expressions of the genes of the melano-



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































Variables of the mRNA expression of different components of the melanocortin 
system were positively related. Among the expressions of TYR, TRP1 and DCT 
mRNAs, a strong positive correlation was noticed both in the skin of the healthy 
controls and in the skin of the vitiligo patients (r > 0.70; p < 0.0001) (Fig. 10a–




Figure 10.  
(a) The relation of the levels of TYR (TYR_HCS), TRP1 (TRP1_HCS) and DCT 
(DCT_HCS) in the skin of the healthy subjects.  
(b) The relation of the levels of TYR (TYR_NLS), TRP1 (TRP1_NLS) and DCT 
(DCT_NLS) in the non-lesional vitiligo skin.  
(c) The relation of the levels of TYR (TYR_LS), TRP1 (TRP1_LS) and DCT 
(DCT_LS) in the lesional vitiligo skin. 
 
 
Positive correlation was noted also between the levels of MC1R and TRP1 in 
the skin of healthy controls (r = 0.47; 95% CI 0.001–0.77; p < 0.05) (Fig. 11a, 
Kingo et al. 2007). Contrarily, no statistically significant correlation between 
variables of MC1R mRNA and the expressions of TYR, TRP1 and DCT 
mRNAs were noticed in the non-lesional and lesional vitiligo skin (Fig. 11 b,c; 





(a) The relation of the levels of MC1R (MC1R_HCS) and TYR (TYR_HCS), TRP1 
(TRP1_HCS) and DCT (DCT_HCS) in the skin of healthy controls.  
(b) The relation of the levels of MC1R (MC1R_NLS) and TYR (TYR_NLS), TRP1 
(TRP1_NLS) and DCT (DCT_NLS) in the non-lesional vitiligo skin.  
(c) The relation of the levels of MC1R (MC1R_LS) and TYR (TYR_LS), TRP1 
(TRP1_LS) and DCT (DCT_LS) in the lesional vitiligo skin. 
 
 
Using QRT-PCR method, mRNA expression levels of eight genes related to 
signal transduction from the melanocortin system to melanogenesis enzymes 
were measured in the lesional and non-lesional skin of the vitiligo patients and 
in the skin of healthy control subjects. All the patients with vitiligo were 
analyzed as the one group. MITF mRNA expression in the lesional skin of the 
vitiligo patients was 3.3-fold lower compared with the non-lesional skin of the 
vitiligo patients (p < 0.0001) and 2.4-fold lower compared with the skin of 
healthy control subjects (p = 0.0001) (Fig.12a, Kingo et al. 2008). LEF1 
expression level in the non-lesional skin of the vitiligo patients was 1.7-fold 
higher than in the lesional skin of the patients (p < 0.0005) (Fig.12b, Kingo et 
al. 2008). USF1 mRNA expression level in the non-lesional skin of the vitiligo 
patients was 1.6-fold higher compared with the skin of healthy control subjects 
(p < 0.01) (Fig.12c, Kingo et al. 2008). No statistically significant differences in 
CREB1 expression levels were found between the lesional and non-lesional 
skin of the vitiligo patients and between the skin of the vitiligo patients and 
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                                   (c) USF1 mRNA expression 
 
Figure 12. Gene expression levels of the MITF, LEF1, and USF1 (relative to house-
keeping gene HPRT mRNA level) in the skin from healthy controls (HCS), the 
non-lesional vitiligo skin (NLS) and the lesional vitiligo skin (LS). 
Bars indicate mean _ S.E.M. *p<0.05, **p<0.01 and ***p <0.001 (compared to HCS 
sample); + p< 0.05, ++ p< 0.01 and +++ p<0.001 (compared to NLS sample). 
 
 
The expression of p38 mRNA was 1.6-fold lower in the lesional skin of the 
vitiligo patients compared with the skin of healthy control subjects (p < 0.005) 
(Fig.13a, Kingo et al. 2008). The expression of PI3KCB mRNA in the lesional 
skin of the vitiligo patients was 1.3-fold lower compared with the skin of 
healthy control subjects (p = 0.01) (Fig.13b, Kingo et al. 2008). The expression 
of RPS6KB1 mRNA in the lesional skin of the vitiligo patients was 1.3-fold 
lower compared with the skin of healthy control subjects (p < 0.05) (Fig.13c, 
Kingo et al. 2008). The expression level of BCL2 mRNA in the non-lesional 
skin of the vitiligo patients was 1.6-fold higher compared with the lesional skin 
of the patients (p < 0.05) (Fig.13d, Kingo et al. 2008). BCL2 expression in the 
non-lesional skin of the vitiligo patients was 2.3-fold higher when compared 
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Figure 13. Gene expression level of the p38, PIK3CB, RPS6KB1 and BCL2 (relative to 
housekeeping gene HPRT mRNA level) in the skin from healthy controls (HCS), the 
non-lesional vitiligo skin (NLS) and the lesional vitiligo skin (LS). 
Bars indicate mean _ S.E.M. *p<0.05, **p<0.01 and ***p<0.001 (compared to HCS 
sample); + p< 0.05, ++ p< 0.01 and +++ p <0.001 (compared to NLS sample). 
 
 
Possible interactions between the expressions of the studied genes were 
examined by the Spearman rank correlation (Tables 12 and 13). In addition, the 
correlations between the expressions of the studied genes and the genes 
encoding enzymes of melanogenesis (TYR, TRP1 and DCT) were examined 
(Tables 12 and 13). In the present study statistically significant positive correla-
tions were found between the expression levels of p38 and PI3KCB, and p38 
and RPS6KB1 both in the skin of the vitiligo patients (respectively, r = 0.75,  
p < 0.001 and r = 0.75, p < 0.001) and in the skin of healthy control subjects 
(respectively, r = 0.92, p < 0.001 and r = 0.82, p < 0.001). The expression levels 
of MITF, PI3KCB and p38 were positively correlated with the mRNA levels of 
TYR, TRP1 and DCT in the skin of healthy control subjects (p < 0.05), but not 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































6.1. Clinical aspects and the presence  
of autoantibodies in vitiligo 
As only few studies have been conducted with adults suffering from vitiligo, it 
is difficult to compare these data with other studies. This could also be the 
reason why our study group showed older mean age of the subjects (44.9 years) 
and longer mean disease duration (16.9 years) compared with previous studies 
(Handa and Kaur 1999; Martis et al. 2002). We could not find statistically 
important differences in the onset of vitiligo and disease duration between 
males and females. In more than half of the cases vitiligo appeared at the age of 
30, but in 15% of the cases late onset (50 plus) was observed, a higher indicator 
than reported earlier (Dogra et al. 2005). Up to now there has been no uniform 
understanding of clinical types or subtypes in vitiligo and the situation is 
complicated as the phenotype of the disease can change during the time. Vitiligo 
vulgaris was the most common clinical subtype in our study and this is in 
consent with many previous published papers (Handa and Kaur 1999; Dogra et 
al. 2005; Liu et al. 2005; Mason and Gawkrodger 2005). Recently the decision 
was made that the term “vulgaris” as the synonym for “common” conveys a 
negative connotation to patients and general public and therefore should not be 
used. VGICC classification renamed vitiligo vulgaris as generalized vitiligo that 
is now the main subtype of nonsegmental vitiligo (Ezzedine et al. 2012). In our 
study vitiligo vulgaris was statistically more prevalent in females and acrofacial 
vitiligo in males, the latter has not been mentioned earlier. Segmental, focal and 
universal subtypes were rare in this study (all together 11% of the cases). Focal 
vitiligo is called now undertermined or unclassified type of vitiligo until more 
definite type can be made on clinical description (Ezzedine et al. 2012). Some 
clinical patterns like localized mucosal subtype, mixed vitiligo and segmental 
subtype in the face region have been more characteristic for the patients in Asia 
and were not observed in our subjects (Hann and Lee 1996; Hann et al. 1997; 
Dave et al. 2002; Mulekar et al. 2006). Segmental vitiligo has been reported 
previously up to 4.5% of adults with vitiligo (Dogra et al. 2005; Mason and 
Gawkrodger 2005). Nowadays the word “segmental” has become a misnomer 
as lesions in Blaschko-linear distribution and lesions not following the com-
monly mentioned „dermatomal” distribution have also been described under 
this type (Schallreuter et al. 2007; Taieb et al. 2008; van Geel et al. 2011a). In 
our study the subjects with segmental and universal vitiligo were affected 
earlier than other subtypes of vitiligo. The segmental subtype was unisegmental 
and did not transform to another subtype. In most studies segmental vitiligo has 
been more characteristic for children and young adults with median age of onset 
12–16 years, but unexpectedly late onset with median age of 41 years of this 
subtype was recently reported in China (Barona et al. 1995; Liu et al. 2005; 
Wang et al. 2013).  
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In our subject group disease had started from the upper limb more than in 
one-third of the cases - that is in agreement with other published papers -, in 
addition to the preferred localisation on lower limb and face region (Handa and 
Kaur 1999; Arycan et al. 2008; Akrem et al. 2008). Few studies have examined 
transformation of the clinical subtypes in vitiligo. In a Japanese study 59% of 
the focal vitiligo cases remained stable, 34% transformed to generalized and 7% 
to segmental type during the years from 0.5 to 8 (Zaima and Koga 2002). The 
survey of 3742 patients in China revealed that more than half of the focal 
vitiligo cases transformed into another clinical type during 3–5 years and 99% 
of all active cases constantly got worce (from focal to acrofacial, segmental, 
vulgaris or universal; from segmental or acrofacial to vulgaris or universal; 
from vulgaris to universal) (Liu et al. 2005). According to the self-reported 
initial location and description of pigment loss the clinical subtype of vitiligo 
was transformed only in 15% of the cases in our study. At the time of 
examination disease was active in 70% of the cases and this is in agreement 
with other studies (Dave et al. 2002; Chun and Hann 1997). Leucotrichia was 
observed almost in half of the cases, but the Koebner phenomenon and mucosal 
involvement were not common in our subjects. Leukotrichia occurs when 
melanocytes are damaged in the hairs inside depigmented area and it shows 
poor prognosis of repigmentation in vitiligo (Dutta and Mandal 1969). There 
has no unambigious method for assessment of Koebner phenomenon in vitiligo; 
this could be the reason why different studies have offered variable results of 
this phenomenon. A new classification of Koebner phenomenon takes into 
consideration historical, clinical and experimental aspects in assessment of this 
phenomenon (van Geel et al. 2011b). In the present study the Koebner 
phenomenon was assessed only on clinical basis and this was the reason why 
the number of the Koebner cases is low.  
Pathogenetic models of vitiligo have implied the presence of external and 
internal predisposing factors in manifesting the pigment loss. In clinical studies 
10–76% of the patients with vitiligo have named factors that had preceded the 
onset or exacerbation of the disease: emotional stress, skin injury, sunburn, 
hormonal changes (Behl and Bhatia 1972; Koo et al. 1996; Verma 2009; 
Manolache and Benea 2007). More than one-third of the subjects in this study 
could report predisposing or aggravating factors of vitiligo: psychological 
stress, mechanical trauma, hormonal changes, sunburn and UVR were among 
the most frequently mentioned. In this study the presence of self-reported 
predisposing factor was statistically significantly associated with female gender 
and more extensive pigment loss (BSA > 10%). Females with vitiligo have 
noticed the influence of hormonal factors on the course of the disease. There is 
the data that metabolites of estrogens can predispose oxidative stress via 
generating hydrogen peroxide and damage DNA of peripheral blood 
lymphocytes in vitiligo (Schallreuter et al. 2006). The exact mechanisms how 
all these factors influence the onset or course of vitiligo, is still obscure. In spite 
of the long mean duration of vitiligo, the subjects with minimal extension 
predominated, as more than a half of the cases of pigment loss did not exceed 
 56
10% of the BSA. It confirms a former opinion that vitiligo is a slowly 
progressing disease with a chronic and very long course. Our study revealed 
that extensive pigment loss (BSA > 10%) was associated with a higher risk of 
the onset of vitiligo at a more early age, up to 20 years, and it was statistically 
more frequently observed in females comparing to males. 
Based on autoimmune hypothesis in the pathogenesis of vitiligo, studies 
have focused on finding associated diseases in vitiligo patients and also in their 
families, but the results have been variable in different populations. In our study 
with the mean age of 44.9 years, more than two-thirds of the subjects had a 
concomitant disease and more than one-third had a disease of autoimmune 
origin. The risk of presence of concomitant autoimmune disease was higher in 
females comparing to males and this is in consistent with previous studies 
(Amerio et al. 2010). Halo nevi were seen in 15.5% of the cases in this study. In 
published papers halo nevi have been associated with vitiligo in up to 31% of 
the cases, they are more characteristic for children and young adults but have 
been shown also in 3.8% of adults at the age 50 years and older (van Geel et al. 
2011c; Dogra et al. 2005). The study of the patients who have vitiligo and halo 
nevi at the same time revealed halo nevi prior to the development of vitiligo in 
61% of the patients with mean time interval 34 months (van Geel et al. 2011c). 
There is a belief that the occurrence of halo nevi may be an initiating factor of 
the pathogenesis of vitiligo. A recent study from Belgium supported the 
hypothesis that halo nevi can represent a distinct clinical condition: patients 
with only halo nevi had significantly less associated autoimmune diseases, were 
less likely to have a family history of vitiligo and were less likely to have the 
presence of the Koebner phenomenon compared with the patients of generalized 
vitiligo (Barona et al. 1995; van Geel et al. 2011c). The lack of association 
between halo nevi and other autoimmune diseases was also revealed in Italy 
(Berti et al. 2011).  
Thyroid disease was the most often reported autoimmune disease in our 
subjects. Autoimmune thyroid disease has been reported from 5% to 24% of the 
children and up to 34% of the adults with vitiligo (Pagovich et al. 2008; Kurtev 
and Dourmishev 2004; Mason and Gawkrodger 2005). Studies from Europe, the 
USA and Asia (excluding China) have demonstrated a higher prevalence of 
thyroid autoimmune disease in patients with vitiligo compared with general 
population (Schallreuter et al. 1994; Alkhateeb et al. 2003; Narita et al. 2011). 
In China the prevalence of thyroid diseases has been low in general population 
and also in patients with vitiligo (Liu et al. 2005; Zhang et al. 2009). An 
elevated risk of thyroid disease among older women with nonsegmental vitiligo 
and in subjects with positive family history of thyroid disease has been 
demonstrated lately in the Netherlands (Kroon et al. 2012). In the present study 
high prevalence of thyroid disease (20.8%), diabetes (13.6%), psoriasis (8.4%), 
rheumatoid arthritis (4.5%) and Addison’s disease (0.6%) was reported by the 
patients also in their families. Again, autoimmune disorders in the family were 
statistically more frequently reported by the females. The elevation of 
autoimmune thyroiditis, pernicious anemia, Addison’s disease, systemic lupus 
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erythematosus has been demonstrated in the first-degree relatives with vitiligo 
in the Caucasian population, and rheumatoid arthritis, psoriasis and chronic 
urticaria in China (Alhateeb et al. 2003; Zhang et al. 2009). Family history of 
vitiligo was positive in 26% of our patients - that is in consent to most published 
papers where the percent remains between 8 and 36 (Handa and Kaur 1999; 
Gopal et al. 2007).  
Autoantibodies have been demonstrated in the range from 2% to 70% in 
different studies in vitiligo (Barona et al. 1995; Bystryn 1989). Studies have 
revealed that the presence of circulating autoantibodies was correlated with a 
long duration of vitiligo and a later disease onset (Mandry et al. 1996; Betterle 
et al. 1985). As opposed to these findings, recent studies in Italy and India have 
highlighted the presence of autoantibodies to be correlated with a short duration 
of vitiligo (Ingordo et al. 2010; Pradhan et al. 2011). The presence of measured 
autoantibodies was established in half of the cases in our adult group and this is 
a high indicator. TPO-Ab was positive more than in one-third of the subjects 
and in 11% of the sera even two different antibodies were detected. The 
previous studies have demonstrated the presence of thyroid microsomal Ab 
from 3.0% to 4.4% of the adult population in Estonia and it is notably lower 
compared to our finding in vitiligo (Uibo et al. 1984, 1998; Metsküla et al. 
2001). Thyroid antibodies have been demonstrated from 18% to 50% of the 
cases of vitiligo in comparative studies in children and adults (Kurtev and 
Dourmishev 2004; Hegedus et al. 1994; Daneshpazhooh et al. 2006). In the 
present study females showed statistically more often positive autoantibodies in 
the blood, especially positive TPO-test comparing to the males. The higher 
prevalence of TPO-Ab has been revealed in young women (18–35 years) with 
vitiligo in Iran (Daneshpazhooh et al. 2006). PCA was positive in 14% of the 
cases of vitiligo in our study and this is higher than 2.5% – 4.2% found in 
Estonian unselected adult population (Uibo et al. 1984, 1998; Metsküla et al. 
2001). The published results of the previous studies concerning PCA in vitiligo 
compared to the controls are contradictory. Many studies have not shown the 
higher prevalence of PCA in vitiligo compared with the control population 
(Carmel 1992; Ottesen 1992; Schallreuter et al. 1994; Zettinig et al. 2003). 
Strong association between PCA and autoimmune gastritis in vitiligo has been 
verified in Italy (Betterle et al 1985; Amerio et al. 2010). The number of 
positive ANA cases in vitiligo did not differ from those observed from the 
unselected Estonian adults (1.8% – 7.4%) (Uibo et al. 1984, 998; Metsküla et 
al. 2001). Most studies have not shown the higher prevalence of ANA in 
vitiligo compared with the control population, except one study in Iran (7%) 
and Korea (12.4%) (Hann et al. 1993; Zettinig et al. 2003; Farrokhi 2005). The 
quantitative value of RF in the positive cases was quite low except one case 
with acute rheumatoid arthritis. Few studies have observed RF in vitiligo, the 
increase of RF in 11% of the cases in vitiligo compared with the controls has 
revealed in Iran (Farrokhi et al. 2005). According to the classification of APS 
by Betterle, 19 cases of APS (17 APS-3 and 2 APS-4) and 35 cases of potential 
APS-3 with only positive TPO-antibodies were discovered among 155 patients 
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with vitiligo and this is a high indicator. Again, females showed statistically 
more often positive APS cases comparing to the males. The subjects with only 
positive antibodies, among them four with AAA, should remain under 
observation for possible manifestation of autoimmune disease. Long follow-up 
of patients with APS has confirmed that “silent” Abs may precede clinical 
manifestation of the autoimmune disease many years and these antibodies are 
predictive for the development of autoimmune disorder in future (Dittmar and 
Kahaly 2003). Autoimmune adrenalitis may develop in 16–40% per year in the 
subjects with positive antiadrenal antibodies (Zosin 2004; Betterle and Volpato 
1998; Muir et al. 1993). AAA have been stronger predictors for adrenal 
insuffiency in children than in adults, 100% vs 32% during the mean follow-up 
of six years (Coco et al. 2006).  
We found several differences between familial and sporadic cases of vitiligo 
in the group of 186 subjects. The patients with family history of vitiligo showed 
a higher risk of earlier onset of the disease (≤ 20 years) and darker skin 
phototype (III–IV). The association between positive family history and the 
earlier onset of vitiligo has been shown in previous and confirmed in recent 
studies (Ando et al. 1993; Laberge et al. 2005; Misri et al. 2009; Alzolibani 
2009). One study has found the association between skin phototype III–IV and 
positive family history in vitiligo (Alzolibani 2009). As opposed to the previous 
studies, our study shows that patients with familial vitiligo have a higher risk 
for widespread depigmentation and the association gets stronger in cases with 
BSA > 50% (Ando et al. 1993; Misri et al. 2009). In this study we verified that 
patients with family history of vitiligo have a higher risk for vulgar vitiligo at 
the onset of the disease. Similarly to other investigators, we could not find 
statistical correlation between positive family history of vitiligo and disease 
activity, areas involved, leukotrichia, mucosal involvement, the Koebner 
phenomenon and triggering factors (Misri et al. 2009; Alzolibani 2009; Laberge 
et al. 2005; Boisseau-Garsaud et al. 2001). Family history of vitiligo was not 
associated with the reported concomitant diseases, including autoimmune 
diseases and positive autoantibodies finding. Despite this, thyroid disease 
among relatives was reported higher in the familial group comparing with 
sporadic cases demonstrated earlier (Laberge et al. 2005). Our results stress the 
importance of female gender in vitiligo, as in sporadic cases female gender 
raises the risk for widespread depigmentation, not shown before. Widespread 
depigmentation (BSA > 10%) was also correlated with prolonged duration of 
vitiligo. We could not reveal any correlation between female gender and atten-
dance of other autoimmune diseases (including thyroid disease) or antibodies 
positivity, as previous studies have found (Klisnick et al. 1998; Daneshpazhooh 
et al. 2006; Amerio et al. 2010). Patients with sporadic vitiligo and very exten-
sive depigmentation (BSA > 50%) have also a higher risk for mucosal depig-
mentation, the presence of triggering factors, PCA and ANA antibodies in the 
sera. At the same time, patients with positive family history of vitiligo and very 
extensive depigmentation (BSA > 50%) have a higher risk for leukotrichia, 
mucosal depigmentation and the presence of triggering factors. This finding 
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supports overall agreement that external factors as well as concurrent auto-
immune conditions predict the widespread eruption in vitiligo.  
Our data do not allow to generalize the autoantibodies overall presence and 
to draw the comparative conclusions about autoantibodies increase in vitiligo as 
only certain autoantibodies were measured in the sera of the patients and control 
group was absent. 
 
 
6.2. Quality of life and emotional state in vitiligo 
Our case-control study in fair-skinned subjects demonstrated the disease-related 
small but close to moderate effect of QoL in vitiligo. The mean DLQI score 4.7 
is significantly higher compared with healthy controls without impact on QoL 
(DLQI 0.6). Our mean DLQI score in vitiligo is in agreement with the studies 
from Belgium (DLQI 4.95), the U.K. (DLQI 4.8) and Indonesia (DLQI 4.4) 
(Kent and al-Abadie 1996; Ongenae et al. 2005b; Chan et al. 2012). The higher 
mean DLQI scores in vitiligo have been shown in Japan, Germany, Iran, 
France, China, India and Saudi Arabia (Tanioka et al. 2010; Radtke et al. 2009; 
Aghaei et al. 2004; Mashayekhi et al. 2010; Kostopoulou et al. 2009; Wang et 
al. 2011; Parsad et al. 2003; Al Robaee 2007; Al-Mubarak et al. 2011). Higher 
DLQI scores are associated with darker skin as the contrast of skin colour in 
dark-skinned people attracts more unwanted attention, which is emotionally 
disturbing and displeasing. In our vitiligo group the mean DLQI was not 
associated with the gender, age, disease duration and family history of vitiligo 
as reported in Malaysian vitiligo patients (Wong and Baba 2012). Studies have 
revealed lower QoL in women because they are more emotional and more 
sensitive about their appearance (Radtke et al. 2009; Belhadjali et al. 2007; 
Borimnejad et al. 2006). Our subjects with vitiligo were disturbed on every 
individual DLQI item compared with healthy volunteers, but more in 
symptoms/feelings, leisure and daily activities than shown previously (Wang et 
al. 2011; Ongenae et al. 2005b). In the group of vitiligo, women scored 
statistically higher in symptoms/feelings compared with men who were more 
impaired in sexual or other personal relations compared with women. The latter 
outcome is opposite to previous results but shows clearly that diverse skin 
colour can cause uncertainty in relations of both genders. Vitiligo has no impact 
on such activities like going to school or work, as pigment loss does not cause 
physical disability and this is in line with other studies (Wang et al. 2011; 
Ongenae et al. 2005b; Radtke et al. 2009; Wong and Baba 2012). In our vitiligo 
group the total DLQI was associated with disease progression, extension, 
depigmentation on the hands, and earlier disease onset. There are no reports in 
the literature confirming that impairment of QoL is associated with the active 
stage of the disease or the earlier disease onset. The progression of pigment loss 
is very disturbing for the patient, as there is no way to get the disease under 
control or to influence its lifelong course, and it undermines their confidence. 
The fact that those who have got the disease earlier in their life and have a 
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higher DLQI score, speaks clearly about difficulties in coping with vitiligo and 
disturbed emotional state (Ongenae et al. 2006). The subjects with depressive-
ness had lower quality of life compared with undepressed vitiligo subjects. 
Cognitive-behavioural therapy could benefit in vitiligo (Papadopoulos et al. 
1999). Most studies have emphasized the association between disease’s 
extension and lower QoL (Wang et al. 2011; Ingordo et al. 2012; Dolatshahi et 
al. 2008; Ongenae et al. 2005b; Parsad et al. 2003). Vitiligo on uncovered areas 
like the face and hands has demonstrated a serious negative impact on QoL 
(Aghaei et al. 2004; Ingordo et al. 2012). Camouflage has decreased the mean 
DLQI score in women with vitiligo by 1–1.5 score points and is highly 
suggested for those who have pigment loss on uncovered areas (Tanioka et al. 
2010; Ongenae et al. 2005a). This may be the reason why our vitiligo group 
showed negative impact only in pigment loss on the hands, not on the face. 
Women have got used to covering faces with makeup but it is more incon-
venient to use camouflage for other parts of the body.  
The patients with psoriasis were more disabled and showed severe QoL 
impairment compared with vitiligo patients and healthy controls. Predictive 
clinical factors for low QoL were disease severity and concomitant arthritis. 
QoL was impaired in every DLQI item with two or three times higher mean 
score compared with vitiligo. The highest scores of DLQI individual scale in 
psoriasis were obtained in symptoms and feelings, daily activities and leisure. 
This profile is in agreement with previous comparative studies (Ongenae et al. 
2005b; Radtke et al. 2009). In this study the interaction of disease and gender 
on DLQI was not observed in psoriasis, as stated earlier (Ongenae et al. 2005b). 
Based on the results of ES-Q, every fifth subject with vitiligo suffered from 
symptoms of depression and anxiety, every third had asthenia and sleep dis-
turbances, but compared with healthy controls these differences did not show 
statistical significance. Studies have reported psychiatric morbidity in up to 
35% of the subjects with vitiligo in Europe but the correlation with disease 
severity or extension has been weak (Mattoo et al. 2001, 2002). It confirms that 
other disease unrelated factors like trait of personality, racial variations, 
socio-cultural and socio-economical factors are affecting psychiatric morbidity 
(Finlay and Ryan 1996). 
In our study the subjects with psoriasis were emotionally more disabled than 
the subjects with vitiligo: 42% had symptoms of depression, 33% had general 
anxiety and 65% had asthenia. The high number of the subjects with disturbed 
emotional state in psoriasis could be explained by the fact that the majority of 
the subjects were recruited from the inpatient department and they had either 
moderate or severe disease with arthritis. The comparison with healthy subjects 
revealed significant impairment of emotional state in every evaluated item in 
psoriasis. Psychiatric cormorbidity in psoriasis has been revealed in 24–53% of 
the patients and our results agree to this estimation (Mattoo et al. 2001; Sharma 
et al. 2001).  
The limitation of this study is, that compared subjects groups were quite 
small to extrapolate the results. Most of the subjects with psoriasis were 
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recruited from the hospital population, which may cause bias in terms of the 
remarkably lower QoL in this group subjects. 
 
 
6.3. Expressional differences of the genes  
of the melanocortin system and intracellular 
melanogenesis pathways in vitiligo  
Systemic response to stress is mainly mediated by the hypothalamic-pituitary- 
adrenal axis (HPA) in the brain. HPA axis has an equivalent, expressed in the 
skin and it coordinates local response to stress. Stress response system in the 
skin contains the melanocortin system that is a part of the cutaneous HPA axis 
(Slominski et al. 2000). In the present study we analyzed the expression of the 
genes of melanocortin system in the skin biopsy samples of the patients with 
vitiligo. The analyzed genes of the melanocortin system in this study were: 
POMC, MC1R-MC5R, ASIP and AGRP.  
Our results reconfirmed the expression of cutaneous stress response system 
in human skin, in spite the fact that there are no previous reports about the 
expression of MC3R mRNA in human skin (Eves and Haycock 2010). Further 
studies should discover the exact cell type capable to express MC3R in the skin. 
The expression profiles of the all five melanocortin receptors were similar 
between the study groups and this can indicate their functional relevance. A 
remarkable expressional difference between lesional and nonlesional skin of 
vitiligo patients (p < 0.0001) was found in the case of MC1R. MC1R showed 
the highest expression in skin samples but the rest of the MCRs had relatively 
low expression levels in the skin. The correlation analysis revealed a moderate 
up to strong positive relation between the levels of mRNA of the different 
melanocortin receptors. The similar expression profile of the all melanocortin 
receptors may be caused by high homology in sequences (Getting 2006). This 
kind of expression profile of the MCRs could also be explained by concomitant 
expression of these genes. Concomitant expression of MC1R and MC2R has 
been reported in human keratinocytes and epidermal melanocytes, MC1R and 
MC4R in human dermal papilla cells (Curry et al. 2001; Moustafa et al. 2002; 
Suzuki et al. 1996; Bohm et al. 2006). The role of the melanocortin system in 
the network of inflammation and pigmentation has been established in the skin 
but the role of markers of the melanocortin system in the pathogenesis of 
vitiligo is indistinct. In our study the expression of POMC mRNA was lower in 
the lesional skin compared with the non-lesional skin in the group of vitiligo (p 
< 0.05). At the same time we did not see the difference in the expression of 
POMC between the non-lesional skin from the vitiligo subjects and the skin 
from healthy controls. The mRNA expression levels of the MCRs, mediating 
the effects of POMC peptides, were decreased in the lesional skin compared to 
the uninvolved skin and increased in the unaffected skin of vitiligo patients 
compared to the healthy subjects. These differences were statistically significant 
(p < 0.01) in MC1R and MC4R. Decreased expression of the MC1R and MC4R 
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in the lesional skin was not surprising. Studies have shown the loss of 
functional melanocytes, a major cell type expressing MC1R, in vitiligo. The 
expression of MC4R has been very low and detected only in dermal papilla 
cells. The high homology in the sequences of MC1R and MC4R and similar 
regulatory regions can predispose comparable down-regulation of these 
receptors in lesional skin in vitiligo. Increased expression of MCRs in the 
nonlesional skin of the patients of vitiligo is not so well known. Skin biopsies 
were taken from the non-sun-exposed areas as UV radiation coud not influence 
the expression of the genes. The distribution of skin phototypes also did not 
differ between the study groups. Such over-expression of MCRs can indicate 
the existence of the compensation system to restore normal pigmentation in 
lesions of vitiligo. Lack of difference of POMC in the non-lesional skin of 
vitiligo and the control skin samples gives a hint that this over-expression is 
induced by systemic influences rather than local ones. TYR, TRP1 and DCT are 
involved in melanogenesis and in the biology of melanocytes. Down-regulation 
of the expression of TYR mRNA has been demonstrated in lesional skin in 
vitiligo (Machado et al. 2005). We have shown a statistically significant 
decrease of TYR expression in the lesional skin compared to the non-lesional 
skin of vitiligo and healthy controls (both p < 0.0001) in our previous study 
(Kingo et al. 2006). In addition to the previously stated, the expression of TRP1 
mRNA by melanocytes has shown a significantly lower level of vitiligo 
compared to melanocytes of the controls (Jimbow et al. 2001). The expression 
of DCT mRNA has not been investigated in vitiligo. In the present study the 
expressions of TRP1 and DCT mRNAs were suppressed in the lesional skin of 
the vitiligo subjects that confirms the decreased melanin synthesis in vitiligo. 
Previous studies have demonstrated the absence or inactivity of melanocytes in 
the lesional area of vitiligo. As the values of mRNA were at a detectable level, 
it explanes that not all melanocytes are destroyed in the lesions.  
In our study the genes involved in the melanin synthesis we up-regulated in 
the uninvolved skin samples of vitiligo patients compared to the samples from 
healthy controls. This difference was statistically significant in the case of 
TRP1. As the overexpression of melanocortin receptors was also detected in the 
same samples, it refers that the activation of enzyme genes in the non-lesional 
skin is a consequence of melanocortin stimulation. Our finding has a functional 
relevance. We suppose that the suppression of melanin production activates 
MCRs transcriptionally through negative feedback to restore normal 
pigmentation. Melanocortins have a wide spectrum of immunomodulatory and 
anti-inflammatory capacities (Luger et al. 2003; Wintzen and Gilchrest 1996; 
Teofoli et al. 1997). The previous studies have reported the increase of the 
expression of pro-inflammatory cytokines (IL-2, TNF-α, IL-6 and INF-γ) in 
lesional skin compared to uninvolved skin of vitiligo patients (Caixia et al. 
1999; Grimes et al. 2004). Such up-regulation of the MCRs in the non-lesional 
skin may be an attempt to inhibit the production of proinflammatory factors and 
to suppress inflammatory response in the lesional skin of vitiligo patients. 
Positive correlation was also found between the levels of MC1R and TRP1 in 
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the skin of healthy controls but not in the skin of vitiligo patients. These 
findings indicate that significant changes in transcriptional regulation of the 
melanocortin and melanin synthesis system take place in the skin in vitiligo.  
In the present study we determined the importance of genes of the signal 
transduction pathways between the melanocortin system and the melanogenesis 
enzymes in the pathogenesis of vitiligo. All investigated genes, except CREB1, 
had statistically significant differences in expression levels between the skin of 
the vitiligo patients and the control subjects. The expression levels of MITF  
(p < 0.0001) and LEF1 (p < 0.0005) in the lesional skin of vitiligo patients were 
lower comparing with the non-lesional skin of vitiligo patients. MITF 
expression in the lesional skin of vitiligo patients was lower when compared 
with the skin of healthy control subjects (p = 0.0001). The difference in MITF 
expression between the lesional and non-lesional skin of vitiligo patients has 
previously been published (Kitamura et al. 2004). To our knowledge, there are 
no expressional studies comparing the level of MITF mRNA in the skin of 
vitiligo patients with the level in the skin of healthy control subjects. In our 
study MITF and LEF1 both showed higher expression in the non-lesional skin 
of the vitiligo patients comparing with the skin of healthy control subjects but 
this finding was statistically non-significant. The expression profile tendencies 
of MITF and LEF1 are similar with the results published in our previous studies 
(Kingo et al. 2006, 2007). Statistically significant positive correlations between 
MITF and TYR (r = 0.50; p < 0.05), TRP1 (r = 0.69; p < 0.01) and DCT (r = 
0.58; p < 0.05) expression levels in the skin of healthy control subjects but not 
in the skin of vitiligo patients let us assume that MITF’s function of raising the 
transcription levels of melanogenesis enzymes is impaired in vitiligo. The 
expression level of p38 (MAPK14) was lower in the lesional skin of vitiligo 
patients when compared with the skin of healthy control subjects (p < 0.005). 
As p38 is an activator of CREB1 and USF1 proteins (Saha et al. 2006), 
therefore lowered p38 level in the skin of vitiligo patients may reduce the 
positive regulation of melanogenesis by CREB1 and USF1. The statistically 
significant positive correlations (p < 0.001) between the expression levels of 
p38 and PI3KCB and the levels of p38 and RPS6KB1 likely assume regulatory 
connections between the mRNA levels of these gene pairs. The finding of 
statistically significant positive correlations between p38 and TYR (r = 0.57; p 
< 0.05), TRP1 (r = 0.76; p < 0.001) and DCT (r = 0.68; p < 0.01) mRNA levels 
in the skin of healthy control subjects and the lack of these correlations in the 
skin of vitiligo patients may imply the impairment of positive regulation of 
melanogenesis by p38 in vitiligo. USF1 expression in the non-lesional skin of 
vitiligo patients was higher when compared with the skin of healthy control 
subjects (p < 0.01). As USF1 regulates the transcription of MC1R, TYR, and 
DCT (Galibert et al. 2001; Schwahn et al. 2005; Corre et al. 2004), it might be 
assumed that the elevated MC1R expression and the tendencies towards higher 
TYR and DCT mRNA levels in the non-lesional skin of vitiligo patients 
demonstrated in our previous studies could be the result of heightened USF1 
expression (Kingo et al. 2006, 2007). However, we could not show statistically 
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significant Spearman correlations between the USF1 mRNA levels and the 
expression levels of MC1R, TYR and DCT. The expression of PIK3CB in the 
lesional skin of vitiligo patients was lower compared with the skin of healthy 
control subjects (p = 0.01). As we know PI3K has an antiapoptotic effect, thus 
the lowered level of PI3K in the lesional skin of the patients may cause 
increased susceptibility of skin cells to apoptosis (Martelli et al. 2006). 
Furthermore, the decreased level of PI3K may increase oxidative stress in the 
lesional skin of vitiligo patients, as the inhibition of PI3K results in reduction of 
the intracellular glutathione concentration (Ramos et al. 2005). These results 
agreed to the findings that the levels of apoptosis and oxidative stress are 
increased in the skin of vitiligo patients (Huang et al. 2002; Lee and Modlin 
2005b; Koca et al. 2004; Schallreuter et al. 1999b). As to MITF and p38, the 
expression levels of PI3KCB correlated with the mRNA levels of 
melanogenesis enzymes in the skin of healthy control subjects (TYR: r = 0.52; p 
< 0.05; TRP1: r = 0.75; p < 0.001; DCT: r = 0.58; p < 0.05) but not in the skin 
of the vitiligo patients. Concequently, we can suppose that there are dys-
functions in the pathways through which PI3K exerts positive effects on 
melanogenesis in the skin of vitiligo. The expression of RPS6KB1 (p70(S6)K) 
was decreased in the lesional skin of vitiligo patients compared with the skin of 
healthy control subjects (p < 0.05). As one of the most important functions of 
RPS6KB1 is to inactivate the translation inhibiting factor PDCD4 in ribosomes 
(Dorello et al. 2006), the decrease in RPS6KB1 expression may cause the 
inhibition of protein synthesis, reduction of cell growth and slowing of cell 
cycle in the skin of vitiligo patients. This support the data that melanocytes 
derived from the skin of vitiligo patients have growth defects in cell culture 
(Puri et al. 1987, 1989). There correlation between the mRNA levels of 
RPS6KB1 and TYR (r = -0.47; p < 0.05) in the lesional skin of vitiligo patients 
was negative. This correlation fits the data according to which the inhibition of 
p70(S6)K with rapamycin increases the expression of tyrosinase (Busca et al. 
1996). The level of BCL2 expression was higher in the non-lesional skin of 
vitiligo patients compared with the skin of healthy control subjects (p < 0.05) 
and lower in the lesional skin of vitiligo patients compared with the 
non-lesional skin of patients (p < 0.05). Nevertheless, the study using flow cyto-
metry, did not demonstrate significant difference in BCL2 expression between 
melanocytes from the non-lesional skin of vitiligo patients and melanocytes 
from the skin of healthy control subjects (van den Wijngaard et al. 2000a). We 
can not deny that the shown difference in our study is due to keratinocytes and 
this needs to be confirmed by further studies.  
 
 
6.4. The future prospects 
1.  In the current study we observed the clinical aspects of vitiligo and our plans 
are to continue with these studies: to find associations between halo nevi and 
different subtypes of vitiligo at a molecular level, to continue with long term 
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follow-up of segmental subtype of vitiligo as the final course of this subtype 
is still obscure.  
2. We hope to perform protein expression measurements in the skin and blood 
samples from vitiligo patients and control individuals. In case of blood, we 
hope to observe both PBMCs and blood sera. We would also like to perform 
immunohistochemical studies with skin and blood cells from vitiligo patients 
and controls. This way we could obtain additional information – namely, in 
which cells exactly our study objects are expressed in different conditions. 
3.  We also perform genetic variation (copy number variation) and single 
nucleotide polymorphism (SNP) analysis in candidate genes with the aim to 





1.  We observed that vitiligo vulgaris is the most frequent clinical subtype of 
vitiligo in adults. The disease has a long-lasting course with a slow pro-
gression during the years. Female gender is associated with the extensive 
pigment loss, the occurrence of autoantibodies in the blood, autoimmune 
disease and APS. 
2.  We verified for the first time that the patients with familial vitiligo have a 
higher risk for vulgar subtype at the beginning of the disease. We also 
revealed that female gender increases the risk for more extensive depig-
mentation in sporadic cases of vitiligo, not shown before. 
3.  We demonstrated the disease-related small impairment of QoL in vitiligo. In 
vitiligo female gender is more influenced in symptoms/feelings and male 
gender in relations, the latter finding has not been revealed before. Lower 
QoL in vitiligo is associated with earlier disease onset, widespread pigment 
loss, disease progression and depigmentation on the hands.  
4.  We revealed that the expression of the genes of melanocortin system and the 
genes of the intracellular melanogenesis pathway is altered in vitiligo. The 
increase of the expression of these genes in the non-lesional skin among 
vitiligo patients has not been previously described. This up-regulation could 
function as a compensation to restore normal pigmentation in depigmented 
lesions of the skin.  
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9. SUMMARY IN ESTONIAN 
Vitiliigo: kliinilised aspektid, elukvaliteet ja  
melanokortiini süsteemi roll haiguse patogeneesis  
Üldteoreetiline taust 
Vitiliigo on omandatud, idiopaatiline haigus, mis melanotsüütide selektiivsest 
destruktsioonist põhjustatuna väljendub naha, karvade ja limaskestade kolde-
lises või generaliseeritud depigmentatsioonis. Vitiliigosse haigestutakse 
enamasti lapse- ja noorukieas, aga haigus võib avalduda ka hilises eas, peale 
viiekümnendat eluaastat. Vitiliigot esineb 0,5–1,0% elanikkonnast Euroopas ja 
USA-s, 0,1–0,6% Hiinas ja kuni 8,8% Indias. Depigmentatsiooni ulatuse ja 
lokalisatsiooni alusel eristatakse mitmeid kliinilisi haigusvorme. Vitiliigo 
klassifitseerimisel pole päris ühtset seisukohta. Varasemast perioodist on levi-
nud vitiliigo segmentaalne ja mittesegmentaalne jaotus, mille aluseks arvatakse 
olevat haiguse erinev patogenees. Detailsema klassifikatsiooni on 21.sajandi 
alguses esitanud Hann ja Nordlund, kes vastavalt depigmentatsiooni paigutusele 
ja ulatusele jaotavad vitiliigo lokaliseeritud, generaliseeritud ja universaalseks 
vormiks ning toovad välja nende vormide alavormid. Uuringud on näidanud, et 
haiguse fenotüüp võib aastate jooksul muutuda. 10–74% vitiliigo haigetest esi-
neb antud haigus lähisugulastel. Vitiliigo esineb sageli koos teiste põletikuliste 
ja autoimmuunhaigustega (türeoidiit, pernitsioosne aneemia, reumatoidartriit, 
Addisoni tõbi, diabeet, erütematoosluupus, psoriaas, jt) ning haigete vereseeru-
mist on leitud mitmeid autoantikehi [kilpnäärme koe vastased (anti-TPO), mao 
parietaalrakkude vastased (PCA), tuumavastased (ANA), neerupealise koore 
vastased (AAA)]. Vitiliigo võib olla autoimmuunse polüendokriinse sündroomi 
üheks väljenduseks, esinedes sagedamini koos kilpnäärme autoimmuunse 
kahjustusega. 
Vitiliigosse haigestumine toob endaga kaasa mitmeid psühhosotsiaalseid 
probleeme. Varasemates uuringutes haiguse mõjust elukvaliteedile ja enese-
hinnangule on näidatud, et vitiliigo võib põhjustada sotsiaalset isolatsiooni, 
tugevat depressiooni (eriti naistel), mõjutada 
inimese seksuaalsuhteid ja valmisolekut abieluks. Peamised elukvaliteediga 
seotud probleemid vitiliigo haigel on: riiete valik, päikesekaitset sisaldavate 
toodete ja varjava meigi kasutamine, aktiivse tegevuse piiramine, inimeste rea-
geering haigusele ja emotsionaalsed probleemid. Uuringutes on dermatoloogia 
elukvaliteedi indeksi (DLQI) skoor vitiliigo haigetel olnud 4,4–17,1. DLQI 
tulemusi mõjutavad rassiline päritolu, nahavärvus, sugu ja kultuuriline taust.  
Vitiliigo tekke põhjused pole tänaseni lõplikult selged. Melanotsüütide 
düsfunktsiooni ja degeneratsiooni põhjustavate patofüsioloogiliste mehhanis-
mide kohta on esitatud mitmeid hüpoteese, milledest levinumad on immuun-, 
neuraalne-, biokeemiline- (oksüdatiivne stress, autotsütotoksiline) ja melano-
tsüütide lühenenud eluea hüpotees. Välja on pakutud vitiliigo konvergentsi-
teooria, mille kohaselt need nimetatud mehhanismid annavad nii eraldi kui ka 
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koos esinedes ühesuguse tagajärje: melanotsüütide isoleeritud kadumise nahast 
ning sõltub patsiendist, millise mehhanismi osatähtsus on kõige suurem. Neu-
raalse regulatsiooni düsfunktsiooni on näidatud erinevate autoimmuunsete ja 
põletikuliste haiguste korral, kuid seda on vitiliigo haigetel vähe uuritud. Neuro-
endokriinse süsteemi olulisusele vitiliigo patogeneesis viitab haiguse avaldu-
mine või ägenemine seoses emotsionaalse stressiga. Melanokortiini süsteem on 
neuroendokriinse süsteemi üks osa, millesse kuuluvad viis melanokortiini 
retseptorit (MC1R-MC5R), nende retseptorite neli agonisti [α-, β- ja γ- 
melanotsüüte stimuleerivad hormoonid (MSH) ja adrenokortikotroopne hor-
moon (ACTH)] ning kaks antagonisti [(agouti-taoline valk (AGRP) ja agouti 
signaliseerimisvalk ehk ASIP)]. Melanokortiini süsteemi peptiidide ekspres-
sioonitase on kõige kõrgem ajus, aga ekspressioon on olemas ka mitmete 
perifeersete kudede rakkudes, kaasa arvatud nahas, kus antud peptiide sekretee-
rivad keratinotsüüdid ja melanotsüüdid. Melanokortiini süsteem täidab nahas 
erinevaid stressivastusega seotud funktsioone, reguleerides pigmentatsiooni, 
põletikku, eksokriinset sekretsiooni, valutundlikkust ja kehatemperatuuri. 
 
Uurimuse põhieesmärgid 
1.  Selgitada välja vitiliigo kliinilised aspektid ja autoantikehade esinemine hai-
gete vereseerumis.  
2.  Uurida haigete emotsionaalset seisundit ja vitiliigo mõju elukvaliteedile ning 
võrrelda saadud tulemusi psoriaasihaigete ja tervete kontrollisikutega. 
3.  Melanokortiini süsteemi rolli selgitamine vitiliigo tekkemehhanismis, hinna-
tes melanokortiini süsteemi peptiidide ning nende retseptorite mRNA 
ekspressioonitasemete erinevusi ning signaaliülekandes melanokortiini 
süsteemilt pigmentatsiooniensüümidele osalevate geenide ekspressioonitase-
mete erinevusi nahas vitiliigohaigetel ja tervetel kontrollisikutel. 
 
Uuritavate grupid ja metoodika 
Haiguse kliiniliste iseärasususte väljaselgitamiseks anketeerisime mõlemast 
soost täiskasvanud (18a. ja vanemad) vitiliigo haigeid, kes reageerisid ajalehes 
avaldatud uuringu üleskutsele või pöördusid SA TÜK nahahaiguste kliinikusse 
ambulatoorsele vastuvõtule. Uuritavaid teavitati suuliselt ja kirjalikult uuringu 
eesmärkidest ja meetoditest, mille järgselt nad allkirjastasid informeeritud nõus-
oleku uuringus osalemiseks. Uuringusse arvamise kriteeriumiks oli vitiliigo 
diagnoos, mis püstitati naha, limaskestade ja karvade vaatlusel loomulikus ja 
ultraviolettkiirte (Woodi lamp) valguses. Uuritavate kohta täideti ankeet, 
millesse märgiti vanus, sugu, rahvus, naha fototüüp, haigestumise aeg, haiguse 
kestus, depigmentatsiooni lokalisatsioon haigestumisel ja uuringu ajal, kliiniline 
alavorm haigestumisel ja uuringu ajal, haiguse aktiivsus, ulatus, Köbneri 
tunnus, haiguse kulg, haigestumist mõjutavad tegurid, kaasnevad haigused, viti-
liigo ja teiste haiguste esinemine perekonnas, eelnev ravi, spontaanne repig-
mentatsioon. Uuringugrupp moodustus 155 haigest (44 M, 111 N; keskmine 
vanus 44,9 ± 16,3 a.; vanuse piirid 18–82 a.). Erinevusi perekondliku ja 
sporaadilise vitiliigo haigusjuhtude vahel võrdlesime 186 uuritaval, kelle seas 
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perekondliku vitiliigoga juhte oli 51 (15 M, 36 N; keskmine vanus 41,7 ±  
15,6 a.; vanuse piirid 18–82 a.) ja sporaadilise vitiliigoga juhte 135 (42 M,  
93 N; keskmine vanus 45,5 ± 16,3 a.; vanuse piirid 18–77 a.) ning antikehad 
olid määratud 173 uuritaval. Autoantikehade määramiseks paluti uuringugruppi 
kuuluvatel isikutel anda ühekordselt 14 ml veeniverd, millega nõustus 141 
uuritavat. Autoantikehade (anti-TPO, PCA, ANA, AAA) ja reumatoidfaktori 
määramine vereseerumis toimus TÜK ühendlaboris kasutatavatel meetoditel. 
ANA, PCA ja AAA määrati kaudsel immunofluorestsentsmeetodil, antigeenina 
kasutati roti maksa (ANA), hiire magu (PCA) ja inimese neerupealise kudet 
(AAA). Sekundaarse antikehana kasutati fluorestseeruva ainega märgistatud 
küüliku polüklonaalset IgG. Anti-TPO määrati kemiluminestsents- ja RF 
immunoturbidimeetrilisel meetodil 
Selgitamaks haiguse mõju elukvaliteedile, küsitlesime mõlemast soost täis-
kasvanuid (vanus ≥18a.) vitiliigoga 54 (22 M, 32 N; keskmine vanus 36,6 ± 
15,0a., keskmine haiguse kestus 11,3 ± 9,8a.) ja psoriaasiga 57 (27 M, 30 N; 
keskmine vanus 40,0 ± 13.3a., keskmine haiguse kestus 18,6 ± 12,7a.) isikuid. 
Kontrollgrupi moodustasid mõlemast soost täiskasvanud 57 (23 M, 34 N, 
keskmine vanus 39,7 ± 12,8a.), kes ei põe vitiliigot ja teisi kroonilisi derma-
toose, kellel puudub perekondlik vitiliigo anamnees. Kontrollgrupi isikud kogu-
ti eelnevalt healoomuliste nahamoodustistega kliinikus konsulteeritud isikute, 
meditsiiniüliõpilaste ja tervisehoolekande töötajate seast. Kõigi uuritavate 
küsitlemisel kasutati Eesti oludele kohaldatud dermatoloogia elukvaliteedi in-
deksi küsimustikku (Finley, 1994) ja üldkasutatavat emotsionaalse enesehinda-
mise küsimustikku (EEK-2, Aluoja jt. 1999). Haiguse kliiniliste tunnuste iseloo-
mustamiseks kasutati vitiliigo korral eelmises uuringus kirjeldatud ankeeti ja 
psoriaasi korral sarnast ankeeti (vanus, sugu, rahvus, naha fototüüp, haigestu-
mise aeg, kestus, kliiniline vorm, haiguse ulatus, kulg, küünte ja liigeste haara-
tus, perekondlikkus, kaasnevad haigused ning haigused perekonnas). 
Geenide ekspressioonitasemete uurimiseks nahas võtsime eelpoolnimetatud 
vitiliigo uuringugruppi kuuluvalt 31 ja 39 isikult lokaalanesteesias 4 mm stant-
siga kaks nahabioptaati, ühe koldest ja teise näiliselt tervest nahast. Võrdlusand-
mete saamiseks võtsime 24, 31 ja 18 tervel kontrollgrupi isikul samal meetodil 
ühe nahatüki. Kontrollisikuteks olid tervisehoolekandetöötajad, meditsiiniüli-
õpilased ja nahahaiguste kliiniku ambulatoorsesse osakonda pöördunud isikud 
näo teleangiektaasiate ja healoomuliste nahanäsadega, kellel ei esinenud viti-
liigot ja teisi kroonilisi dermatoose ning kellel puudus perekondlik vitiliigo 
anamnees. TÜ füsioloogia instituudis määrasime nahas TaqMan® QRT-PCR 
meetodil melanokortiini süsteemi peptiidide ja nende retseptorite mRNA 
ekspressiooni tasemed ja signaaliülekandes melanokortiini süsteemilt pig-
mentatsiooniensüümidele osalevate geenide ekspressiooni tasemed. 
Andmete analüüs vitiliigo haigete alagruppide võrdlemisel toimus hii-ruut 
testi ja Microsoft Office 2008 Excel (Microsoft Corporate, Redmond, WA, 
USA) tarkvara abil. Elukvaliteedi uuringus testisime normaaljaotusele vastavaid 
andmeid parameetriliselt paaritu t-testi teel ja normaaljaotusele mittevastavaid 
andmeid Mann-Whitney t-testi abil. Geenide ekspressiooni määramisel 
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kasutasime mRNA kvantifitseerimiseks võrdleva tsükliläve (Ct) meetodit (ing-
lise keeles comparative cycle threshold method), sihtmärk-geeni ekspressiooni-
tase normaliseeriti endogeense võrdlusgeeni HPRT1 suhtes. Geenide mRNA 
ekspressioonitasemeid iseloomustava parameetrina kasutasime 2-δCt väärtusi. 
Geenide ekspressioonitasemete gruppidevahelised erinevusted kordades leiti kui 
võrreldava grupi 2-δCt ja referentsiks valitud grupi 2-δCt suhe. Normaaljaotusele 
vastavust testisime Kolmogorov-Smirnov’i testi abil. Geeniekspressiooni tase-
mete mõõtmistulemuste jaotus selle meetodi põhjal ei vastanud Gaussi jaotu-
sele. Gruppidevaheliste erinevuste testimiseks kasutasime Mann-Whitney 
U-testi ja Kruskal-Wallis’e testi. Ühe grupi kahe parameetri vaheliste suhete 
uurimiseks kasutasime korrelatsioonianalüüsi, korrelatsiooni tugevust hinda-
sime Spearman’i korrelatsiooni meetodi abil. Andmetöötlus toimus GraphPad 
Prism 4 tarkvaraga (GraphPad Software, San Diego, CA, USA). Kõigi testide 
puhul lugesime statistiliselt oluliseks p väärtuse <0,05.  
 
Tulemused 
Vitiliigo avaldus 30.eluaastaks enam kui pooltel juhtudest, 15%-l esines hiline 
(≥50a.) haigestumine. Vitiligo vulgaris oli levinum kliiniline alavorm nagu ka 
mujal maailmas, esinedes 81%-l haigetest. Kliiniliste alavormide võrdlemisel 
ilmnes statistiliselt oluline erinevus haigestumise vanuse osas segmentaalse ja 
akrofatsiaalse (P < 0.001), segmentaalse ja koldelise (P < 0.05), segmentaalse ja 
hariliku (P < 0.05), universaalse ja akrofatsiaalse (P < 0.05) alavormi korral. 
Segmentaalne ja universaalne vitiliigo avaldusid juba lapseeas, kuid esinesid 
antud täiskasvanute grupis harva (6%). Pigmendi kadu algas sagedamini üla-
jäsemelt ja kehatüvelt, aja jooksul oli kliiniline vorm muutunud 15%-l. Köbneri 
tunnus esines 15%-l ja leukotrichia 48%-l haigetest. Enam kui pooltel vitiliigo 
haigetest ei ületanud pigmendi kadu 10% nahapinnast ja haigus oli aktiivses 
faasis 70%-l. Pigmendi kadu esilekutsuvaid tegureid nimetas 39%, olulisemad 
olid stress, mehhaaniline trauma ja hormonaalsed nihked. Välise teguri 
olemasolu oli statistiliselt oluliselt seotud naissooga (P = 0.003) ja laialdasema 
(üle 10% nahapinnast) pigmendi kaoga (P = 0.0001). Kaasnev autoimmuun-
haigus oli diagnoositud 37%-l, sagedamini kilpnäärme haigus (17%), haloga 
neevus (16%), psoriaas (5%), reumatoidartriit (4%). Vitiliigo esines perekonnas 
26%-l uuritavatest, kilpnäärme haigus 21%-l, psoriaas 8%-l, reumatoidartriit 
5%-l, Addisoni tõbi 1%-l. Vereseerumis leidus autoantikehi 50%-l: TPO-ak 
35%-l, PCA 12%-l, RF 8%-l, ANA 3.5%-l ja AAA 2.9%-l uuritavatest. 
Kogutud andmete alusel esines 19-l haigel APS ja 35-l juhul oli tegemist 
võimaliku APS-3 (seerumis TPO-ak, kliiniliselt uurimata). Meestega võrreldes 
esines naistel statistiliselt enam kaasnevat autoimmuunhaigust (P = 0.011), 
vereseerumi positiivsust autoantikehadele [(P = 0.045), TPO-ak (P = 0.013)], 
APS (P = 0.007) ja autoimmuunhaigust perekonnas (P = 0.042).  
Perekondliku ja sporaadilise vitiliigo juhtude võrdlemisel selgus, et pere-
kondliku vitiliigo haigetel on suurenenud mitmed riskid: haigestuda 20.elu-
aastaks (P = 0,008; OR 2,407; 95%CI 1,246–4,649), ulatuslikumaks depig-
mentatsiooniks (BSA üle 10%: P = 0,004; OR 2,606; 95% CI 1,341–5,064 ja 
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BSA üle 50%: P = 0,001; OR 3,856; 95%CI 1,597–9,310), hariliku vitiliigo 
vormi tekkeks (P = 0,008; OR 2,966; 95%CI 1,289–6,821) ja kilpnäärme-
haiguse esinemiseks perekonnas (P = 0,03; OR 2,200; 95% CI 1,064–4,548). 
Sporaadilistel juhtudel olid naissugu ja haiguse kestus ≥10a. riskiteguriteks 
ulatuslikuma depigmentatsiooni tekkel (BSA > 10%: P = 0,001; OR 3,984; 95% 
CI 1,668–9,520 ja P = 0,001; OR 3,560; 95% CI 1,681–7,539; vastavalt). Väga 
laialdane depigmentatsioon (BSA > 50%) suurendas mõlemas grupis riski 
pigmendi kaoks limaskestadel (perekondlik P = 0,01; OR 8,000; 95% CI 1,261–
50,772; sporaadiline P = 0,004; OR 7,375; CI 1,550–35,096), vallandava teguri 
olemasoluks (perekondlik P = 0,0005; OR 10,560; 95% CI 2,451–45,497; 
sporaadiline P=0,004; OR 7,630; 95% CI 1,580–36,858) ja leukotrihhiaks, mis 
oli statistiliselt oluline perekondlike juhtude grupis (P = 0,0001; OR 26,923; 
95% CI 3,178–228,060). Sporaadiliste vitiliigo juhtude korral suurendas 
laialdane depigmentatsioon (BSA > 50%) riski autoantikehade olemasolule 
vereseerumis (P = 0,03; OR 4,941; 95%CI 1,005–24,300), eriti PCA ja ANA 
osas (P = 0,04; OR 4,457; 95% CI 0,994–19,978 ja P = 0,0002; OR 28,250; 
95%CI 2,307–345,989 vastavalt). Uuring näitas, et vitiliigo mõju elukvalitee-
dile on heledanahalistel täiskasvanutel väike (DLQI keskmine 4,7), see on 
oluliselt madalam psoriaasi mõjust elukvaliteedile (DLQI keskmine 13,1; P < 
0,001), aga oluliselt kõrgem mõjust tervetel kontrollidel (DLQI keskmine 0,6; P 
< 0,001). Kontrollisikutega võrreldes avaldas vitiliigo DLQI skaalal statistiliselt 
olulist mõju sümptomitele ja tunnetele (P < 0,001), aktiivsele tegevusele (P < 
0,001), vaba aja veetmisele (P < 0,001), aga ka ravimisega seotud toimingutele 
(P < 0,01) ja isiklikele suhetele (P < 0,05). Sugu oli seotud kõrgema skooriga 
sümptomite/tunnete skaalal naistel (P = 0,003) ja suhete skaalal meestel (P = 
0,040). Vitiliigo korral oli DLQI seotud varase haigestumisega (≤ 20a. vs >20a.; 
P = 0,040), haiguse aktiivsusega (P = 0,006), depigmentatsiooni ulatusega (BSA 
≤ 10% vs > 10%; P = 0,005) ja pigmendi kaoga labakätel (P = 0,008). Psoriaasi 
haigetel oli DLQI seotud lööbe ulatuse ja tugevuse indeksiga (PASI ≤ 10 vs 
≥20; P = 0,027) ning kaasneva artriidiga (P = 0,019). Vitiliigo haigetel ei esine-
nud tervete kontrollidega võrreldes statistiliselt olulisi erinevusi emotsionaalse 
enesehinnangu kogu skaala (depressioon, üldine ja sotsiaalne ärevus, paanika, 
asteenia, unetus) keskmiste skooride osas. Vastavalt EEK-2 esines depressiivsus 
20% vitiliigo haigetest, kellel oli ka mõju elukvaliteedile oluliselt suurem kui 
mittedepressiivsetel vitiliigo haigetel (DLQI 7,2 vs 4,2; P < 0.05). Vitiliigoga 
võrreldes avaldas psoriaas olulist mõju depressiooni (P<0.05), üldise ärevuse (P 
< 0.01) ja asteenia (P < 0.05) skaalal ning kontrollisikutega võrreldes skaala 
kõigi hinnatavate tunnuste osas. 
Melanokortiini süsteemi peptiidide, nende retseptorite ja signaaliülekandes 
melanokortiini süsteemilt pigmentatsiooniensüümidele osalevate geenide 
mRNA ekspressioonitasemete hindamine nahas vitiliigo haigetel ja tervetel 
kontrollisikutel tõi välja mitmeid erinevusi. Selgus, et vitiliigo haigete depig-
menteerunud nahas on POMC’i mRNA ekspressioon 1,9 korda madalam kui 
haigete visuaalselt kahjustamata nahas (p < 0,05). MC1R’i ekspressioonitase oli 
vitiliigo haigete kahjustamata nahas 1,6 korda kõrgem ekspressioonist kontroll-
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isikute nahas (p < 0,01) ja vitiliigokoldes 2,1 korda madalam ekspressioonist 
haigete kahjustamata nahas (p < 0,0001). MC4R’i ekspressioon oli vitiliigo 
haigete kahjustamata nahas 1,9 korda kõrgenenud võrreldes kontrollisikute 
nahaga (p < 0,01) ja ekspressioon haiguskoldes langenud 2,5 korda võrreldes 
haigete kahjustamata nahaga (p < 0,01). Sama trend esines ka MC2R, MC3R ja 
MC5R puhul, kuid need erinevused ei olnud statistiliselt olulised. TYR’i 
ekspressioonitase vitiliigokoldes oli 14,0 korda madalam võrreldes kahjus-
tamata nahaga (p < 0,0001) ja 8,5 korda madalam võrreldes tervete kontroll-
isikute nahaga (p < 0,0001), ekspressiooni tõus vitiliigo haigete kahjustamata 
nahas võrreldes kontrollisikute nahaga ei olnud statistiliselt oluline. TRP1 
mRNA ekspressioon vitiliigokoldes oli 6,8 korda madalam ekspressioonist 
tervete kontrollisikute nahas (p < 0,0001) ja 19,7 korda madalam ekspres-
sioonist vitiliigo haigete kahjustamata nahas (p < 0,0001), ekspressioon haigete 
kahjustamata nahas oli 2,9 korda kõrgem võrreldes tervete kontrollisikute 
nahaga (p < 0,05). DCT mRNA ekspressioon haiguskoldes oli 7,6 korda 
madalam ekspressioonist tervete kontrollisikute nahas (p < 0,0001) ja 12,9 
korda madalam ekspressioonist vitiliigo haigete terves nahas (p<0,0001), eks-
pressiooni kõrgenemine haigete kahjustamata nahas võrreldes tervete kontroll-
isikute nahaga ei olnud statistiliselt oluline (p = 0,14). MITF-M’i mRNA eks-
pressioon haiguskoldes oli 3,3 korda madalam kui haigete kahjustamata nahas 
(p < 0,0001) ja 2,4 korda madalam kui tervete kontrollisikute nahas (p = 
0,0001). LEF1 ekspressioon oli vitiliigo haigete kahjustamata nahas 1,7 korda 
kõrgem kui haiguskoldes (p < 0,0005). USF1 mRNA ekspressioonitase vitiliigo 
haigete terves nahas oli 1,6 korda kõrgem kui tervete kontrollisikute nahas (p < 
0,01). CREB1 ekspressioonitasemetes ei olnud statistiliselt olulisi erinevusi 
vitiliigo haigete kahjustatud ja kahjustamata naha vahel, aga ka võrdluses 
tervete kontrollisikute nahaga. CREB1 ekspressioon oli statistiliselt mitte-
oluliselt kõrgenenud haigete kahjustamata nahas võrreldes kahjustatud naha ja 
kontrollisikute nahaga. p38 mRNA ekspressioon vitiliigokoldes oli 1,6 korda 
langenud võrreldes tervete kontrollisikute nahaga (p < 0,005). PIK3CB mRNA 
ekspressioon vitiliigokoldes oli 1,3 korda langenud võrreldes tervete kontroll-
isikute nahaga (p = 0,01). RPS6KB1 mRNA ekspressioon vitiliigokoldes oli 1,3 
korda langenud võrreldes tervete kontrollisikute nahaga (p < 0,05). BCL2 
mRNA ekspressioonitase vitiliigo haigete kahjustamata nahas oli 1,6 kõrgem 
kui haiguskoldes (p < 0,05) ja ekspressioon haigete kahjustamata nahas oli 2,3 
kõrgem ekspressioonitasemest tervetel kontrollisikutel (p < 0,05). Spearmani 
korrelatsioonianalüüs näitas tugevat positiivset korrelatsiooni TYR, TRP1 ja 
DCT mRNA tasemete vahel nii vitiliigo haigete kahjustamata ja kahjustatud 
nahas kui ka tervete kontrollisikute nahas (r > 0,70; p < 0,0001). Positiivne 
korrelatsioon ilmnes tervete kontrollisikute nahas MC1R ja TRP1 tasemete 
vahel (r = 0,47; p < 0,05). Korrelatsioonid MC3R ja MC4R (r > 0,79), p38 ja 
PI3K (r > 0,63), PI3K ja p70(S6)K (r > 0,55) ning p38 ja p70(S6)K (r > 0,69) 
ekspressioonitasemete vahel olid statistiliselt olulised (p < 0,001) nii 
vitiliigohaigete nahas kui ka kontrollisikute nahas. Statistiliselt olulised (p < 
0,05) olid ka korrelatsioonid MITF’i ja p38 (r > 0,43), MITF’i ja PIK3CB (r > 
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0,35) ning MITF’i ja p70(S6)K (r > 0,51) mRNA tasemete vahel nii vitiliigo-
haigete nahas kui ka kontrollisikute nahas.  
Antud töös esineb piiranguid. Saadud tulemused ei võimalda teha üldistusi 
autoantikehade esinemise kohta vitiliigo haigetel, kuna seerumis määrati ainult 
teatud autoantikehi ja puudus kontrollgrupp. Uuritavate arv elukvaliteedi 
uuringugruppides oli väike, mis ei luba teha kaugeleulatuvaid järeldusi. Oluli-
selt madalam elukvaliteet psoriaasi haigetel võib olla mõjutatud nende uurita-
vate värbamisest statsionaarsest osakonnast. Uurisime geenide ekspressiooni 
täisnaha koeproovides, mis ei võimalda täpsustada milliste rakkudega on 




1.  Uurimus selgitas välja, et vitiligo vulgaris on vitiliigo enamesinev kliiniline 
alavorm täiskasvanutel. Vitiliigo kulg on pikaajaline, haigus progresseerub 
aeglaselt aastate jooksul. Naissugu on seotud ulatuslikuma pigmendi kaoga, 
autoantikehade esinemisega vereseerumis, kaasneva autoimmuunhaiguse ja 
APS-ga.  
2. Antud uurimus näitas esmakordselt, et perekondliku vitiliigoga haigetel on 
kõrgenenud risk vitiligo vulgaris’e väljakujunemiseks varases haigusjärgus. 
Leidsime, et naissugu on oluliseks riskiteguriks ulatusliku depigmentatsiooni 
tekkel sporaadilistel juhtudel, mida pole varem näidatud. 
3.  Leidsime, et vitiliigo mõju elukvaliteedile on täiskasvanutel väike. Elukvali-
teedi indeksi analüüs näitas, et naissugu on enam mõjutatud sümptomite/ 
tunnete ja meessugu isiklike suhete skaalal, viimast pole varem rõhutatud. 
Madalam elukvaliteet on vitiliigo haigetel seotud varasema haigestumisega, 
ulatusliku pigmendi kaoga, haiguse progresseerumisega, depigmentatsiooni-
ga labakätel. 
4.  Selgitasime välja, et melanokortiini süsteemi geenide ja signaalülekandes 
melanokortiini süsteemilt pigmentatsiooniensüümidele osalevate geenide 
ekspressioon on vitiliigo korral muutunud. Melanokortiini süsteemi geenide 
ekspressioonitasemete tõusu vitiliigo haigete visuaalselt kahjustamata nahas 
ei ole varem näidatud ning see viitab kompensatoorse mehhanismi olemas-
olule taastamaks normaalset pigmentatsiooni haiguskolletes.  
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